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O vírus Epstein-Barr é um gamma-herpesvirus que infecta células epiteliais e células B 
“naive”. Com uma prevalência de cerca de 95% na população mundial, é geralmente 
adquirido durante a infância ou adolescência, sendo responsável por uma condição clínica, 
designada mononucleose infeciosa, que não ameaça a vida. No entanto, particularmente em 
indivíduos imunodeprimidos este vírus está implicado no aparecimento de linfomas e de 
alguns carcinomas. A presença de “stable intronic sequence RNAs” (sisRNAs) codificados 
pelo EBV foi detectada em linhas celulares EBV-positivas pela primeira vez em 2013 e a sua 
função no ciclo de vida do vírus tem sido até agora desconhecida. Aqui é reportada a 
produção do primeiro vírus knock-out para o sisRNA-1 e o estudo preliminar do seu 
comportamento na infecção de células B. Os resultados obtidos a partir da monitorização da 
proliferação celular e análises de FACS revelaram que a delecção do intrão codificado pelo 
sisRNA-1 causa um atraso na proliferação celular no dia 8-pós infecção de células B, mas não 
impede a proliferação mais tardia e a formação de LCLs. A transcrição de genes virais como o 
LMP1 e a utilização dos promotores Cp vs Wp, bem como a expressão de proteínas virais 
foram analisadas, mas nenhuma diferença significativa foi encontrada entre os vírus WT e o 
sis1KO. Permanece por determinar se os efeitos observados são de facto uma consequência 
do sisRNA-1 ou da disrupção do “splicing” de BHRF1 que consideramos ser uma 
















Epstein-Barr virus (EBV) is a gamma-herpesvirus that infects epithelial cells and naïve B 
cells. With a prevalence of about 95% in the world population, it is generally acquired during 
childhood or adolescence and is responsible for a non-threatening clinical condition called 
infectious mononucleosis. However, particularly in the immunosuppressed this virus is 
implicated in the pathology of lymphomas and some carcinomas. The presence of EBV-
encoded stable intronic sequence RNAs in EBV-positive cell lines was detected for the first 
time in 2013 and their role in the EBV’s life cycle is not yet known. Here is reported the 
generation of the first virus knock-out virus for sisRNA-1 and the preliminary study of the 
virus’ behaviour in B cell infection. Evidence found by monitoring cell proliferation through 
microscopy and FACS analysis shows that knocking out the intron that encodes sisRNA-1 
causes proliferation impairment by day 8 after B cell infection, but doesn’t impede later 
proliferation and outgrowth of LCLs. Viral transcription of LMP1 and Cp vs Wp promoter 
usage was analysed as well as viral protein expression of the EBNAs but no significant 
differences between WT and sis1KO where found. It remains to be determined if the effects 
observed where in fact a consequence of the lack of sisRNA-1 or due to the disruption of 
















I would like to express my deepest gratitude to my supervisor, Dr. Rob White, for his 
unlimited support and advice, for his humanity, patience and good-humour and most of all of 
the insights he shared about his large understanding of viral genetics and the EBV biology. 
I also have to thank Dr. Richard di Palermo, for guiding me in the lab work during the 
first months, for his friendship and companionship, and for teaching me the basis about 
cricket. 
To Dr. Agniezska Szymula I thank for all of the help with the B cell infections and for 
providing me with so much data and tools from her PhD, apart from being such a good friend. 
To Adam Gillman, for guiding me through the world of buffy coats and FACs 
analysis. 
To Gillian Parker, for being the person holding the lab together, and making sure 
everything works at 100%. 
To all of the other members of the White, Allday, Martens and Pharrel’s labs, for the 
incredible work environment they create, their sympathy, kindness and friendship. They made 
my period in London much more interesting. 
I would also like to extent my gratitude to Mónica Coutinho, the Erasmus Coordinator 
of my home university for her commitment to find the financial support for this period 
abroad. 
Also to Professors Tim Hogg, António Rangel and Célia Manaia for kindly agreeing to 
provide their recommendation letters, that were crucial to help me get accepted in Imperial. 
Finally, to my dear and supportive parents, to my brother and to my loving boyfriend, 
for always standing by me and giving me encouragement to go on when all of the Science 














Resumo ..................................................................................................................................... III 
Abstract ...................................................................................................................................... V 
Acknowledgments ................................................................................................................... VII 
Abbreviations ........................................................................................................................... XI 
Chapter 1: Introduction ...............................................................................................................1 
1.1      EBV epidemiology and relevance of its study .............................................................1 
1.2  EBV life cycle – the Germinal Centre Model ..............................................................2 
1.3 Oncogenic processes in EBV positive cells .................................................................4 
1.4 Genetic Regulation of the EBV genes ..........................................................................5 
1.5 Ability to induce B cell immortalization: in vitro generation of LCLs ........................7 
1.6 Splicing events in latency III infected B cells ..............................................................8 
1.7 Non-coding RNAs in viruses .....................................................................................10 
1.8 SisRNAs found in W repeats of EBV ........................................................................12 
1.9 Previous evidence for the importance of EBV sisRNAs in B cell infection ..............13 
1.10 Aims and hypothesis ..................................................................................................16 
Chapter 2 : Materials and Methods ...........................................................................................17 
2.1 DNA Manipulation and Cloning ................................................................................17 
2.2  Cell Culture ................................................................................................................24 
2.3      Viral Particle Production and Isolation ......................................................................26 
2.4 Infection of Primary B cells and Early Infection Study .............................................28 
2.5 RNA Extraction and Analysis ....................................................................................30 
2.6 Protein Extraction and Analysis .................................................................................31 
Chapter 3: Results .....................................................................................................................33 
3.1      Generation of six W repeat constructs and quality control ........................................33 
3.2      Generation of recombinant BACs ..............................................................................37 
3.3      Maxi-prep: Isolation of supercoiled DNA for Transfection .......................................39 
3.4      Episome integrity test in the producer cell lines ........................................................40 
3.5      Pre-existing Cell Lines ...............................................................................................41 
3.6      Infectivity test – Raji Cell Infections .........................................................................43 
3.7      PBL Infection .............................................................................................................44 
3.8      Primary B cell Infection .............................................................................................45 
3.9      Proliferation Assays ...................................................................................................48 
3.10    RNA expression from B cell infection .......................................................................52 
3.11    Protein Expression Analysis in LCL grown from infected B cells ............................57 
Chapter 4: Discussion ...............................................................................................................58 
4.1     Attempt to establish 6W repeat arrays failed for some of the mutants .......................58 
4.2     Differences in the episomes rescued from the producer cell lines are not significant 59 
4.3     Differences in viral titres might be a consequence of the lack of sisRNA-1 ..............60 
4.4     Importance of infections in different donors ...............................................................61 
	X	
4.5     Higher cell death by day 8 post-infection for LPKO and sis1KO……………...……61 
4.6     SisRNA-1 is not essential in transformation of B cells by EBV but it seems to 
improve early proliferation……...……………………………………………………….....62 
4.7     B cells infected with LPrevi show a delayed growth and ultimately died……….......63 
4.8     Cp vs Wp usage…………………………………………………………………… ...61 
4.9     LMP1 expression is not substantially different……………………………………...64 
4.10   Protein expression is not conclusive…..…………………………………………….65 
Chapter 5: General Conclusions ...............................................................................................66 
Chapter 6: Future Work ............................................................................................................67 
6.1     Finish the construction of mutant viruses and repeat infections .................................67 
6.2     Following up on the defective features of sisRNA-1 ..................................................68 























~ - approximately O/N - Over Night 
BAC -  Bacterial Artificial 
Chromosome           ORF - Open Reading Frame 
bp  -  base pairs P/S -  Penicillin / Streptomycin 
BSA - Bovine Serum Albumin PBL - Peripheral Blood Leucocytes 
C EBP - CCAAT enhancer 
binding proteins 
PBS - Phosphate-Buffered 
Saline 
cis-NAT - cis Natural Antisense 
transcripts 
rRNA - ribosomal RNA 
Cm -  Chloramphenicol RBP-Jk -  Recombination Signal Binding 
Protein for Immunoglobulin Kappa J 
Region 
ddH20 - double deionized water Rev - Revertant 
DNA - Deoxyribonucleic Acid RGU - Raji Green Units 
EBNA - EBV Nuclear Antigen RNA - Ribonucleic Acid 
EBV - Epstein Barr Virus Rpm - rotations per minute 
ED L1 – LMP1 proximal promoter RT - Room Temperature 
h - hours RT qPCR - Real Time Quantitative  
Polymerase Chain Reaction 
HCMV - Human Cytomegalovirus s - seconds 
hnRNP - Heterogeneous 
Ribonuclear Protein Complexes 
sisRNA - stable intronic 
sequence RNA 
HRP - Horseradish Peroxidase snRNA - small nuclear RNA 
IL - Interleukine snoRNA - small nucleolar RNA 
JAK/STAT - Janus Kinase / 
Signal Transducer and Activator 
of Transcription  
SNP - Single Nucleotide 
Polymorphism 
Kan/K - Kanamycin T - Temperature 
KO - Knock Out tRNA - transference RNA 
LCL - Lymphoblastic Cell Lines Tet - Tetracycline 
LMP -  Latent Membrane Protein TPA - Phorbol Ester 
MCMV - Murine Cytomegalovirus TR L1 – LMP1 distal promoter 
min - minutes UV - Ultraviolet 
MOI - Multiplicity of Infection Vol – Volume 
mRNA - messenger RNA WB -  Western Blot 
ncRNA - non coding RNA WT - Wild Type 






























1.1 EBV epidemiology and relevance of its study 
 
Epstein-Barr virus belongs to the family of gamma-herpesviruses, and can infect B 
cells or epithelial cells. This is a dsDNA virus of about 170 kb, containing a linear DNA in 
the virion that circularizes to form an episome within the host cell. Carriers usually became 
infected during childhood, and they rarely present any symptoms at this age. The infection of 
B lymphocytes and their proliferation in adults and teenagers that haven’t been infected 
during childhood, can result in infectious mononucleosis. EBV is generally transmitted 
through saliva, when the virus establishes a lytic replication cycle in the oropharynx. It has 
been shown that even healthy carriers have a constant shed of virus in saliva, although most 
of the viral particles produced are intact but uninfective (Hadinoto et al. 2009). Most of the 
viral particles are thought to result from replication in oropharyngeal epithelial cells, where 
most of the lytic stage of the virus life cycle occurs (Tsao et al. 2012) . 
According to the World Health Organization (2014), about 95% of the world adult 
population has had contact with the virus at some point in their lives and present immune 
memory against it, although just a minority develops any symptoms.  
EBV was first discovered in 1964, when it was observed by electron microscopy (at 
that time a technique still in its early stage) in a form of malignant B cell lymphoma,  named 
Burkitt lymphoma, endemic in children in some regions of Africa (Epstein & Achong 1964). 
It was later identified as the etiological agent of infectious mononucleosis (Henle et al. 1968).  
The geographical and climate related distribution of the disease first provoked suspicions that 
an infectious agent could be related to its development (Hadinoto et al. 2009). In fact, it was 
the first virus to be acknowledged as a human oncogenic virus, although this fact has been a 
source of discussion for decades. Its ability to induce tumours including Burkitt lymphoma, 
Hodgkin lymphoma and Immunoblastic Lymphomas in the immunosuppressed, particularly 
in transplant and AIDS patients usually after post-latency reactivation is now largely accepted  
(reviewed in (Klein et al. 2007; Young & Rickinson 2004). The EBV-positive lymphomas 
display EBV genes being transcribed in all of the tumorous cells and expressing a particular 
subset of latent proteins (Young & Rickinson 2004)). The virus is also a co-factor responsible 
for some epithelial carcinomas, such as nasopharyngeal and gastric carcinomas, although 
immortalization of epithelial cells in vivo is rare and doesn’t occur unless there is cellular 
factors contributing to it (Tsao et al. 2012). Worldwide, EBV was estimated to be responsible 
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for for 5.5% of all the new cases of infection-related cancers in 2012 (Plummer et al. 2016). 
EBV is also epidemiologically associated with autoimmune diseases, particularly systemic 
lupus erythematosus and multiple sclerosis (Füst 2011), as well as artritis reumatoide. 
When Epstein identified it as a novel herpesvirus, (Epstein et al 1964) he observed 
that unlike other known members of the family, that would quickly cause in vitro cells to die, 
this virus would instead remain in the cells in a biologically inert state (Epstein 2015). This is 
one of the key aspects of EBV, essential for the understanding of its biology, that will be 
explained in the next section. 
1.2  EBV life cycle – the Germinal Centre Model 
 
The most widely accepted model for  EBV’s persistence in vivo is known as the 
Germinal Centre Model (Thorley-Lawson et al. 2008). EBV presents 3 different latency 
profiles, in which specific subsets of viral genes are translated, that correlate with specific 
stages of the B cell life cycle, including the cell’s activation and maturation inside the lymph 
nodes (figure 1.1).      
It is thought that using the oral cavity, the viral particles reach and cross the surface of 
the tonsillar epithelium, where they infect naïve B cells. However, it is possible that other 
type of cells are infected primarily, similarly to what has been described for MHV68, that has 
a pre-infection stage in monocytes (Gillet et al. 2015; Frederico et al. 2012). After entering 
the cell, the virus expresses the full growth programme known as latency III, where all of the 
6 EBNAs (EBV Nuclear Antigens), and the latent membrane proteins LMP1 and LMP2A are 
being expressed; this viral protein expression, which is highly immunogenic, among with the 
phonotypical change cells undergo, induces activation markers and co-stimulatory molecules. 
This contributes to the development of the T cell response and most of the infected cells are 
thought to be recognized and killed by cytotoxic T cells (Dolcetti 2007). 
However, activated cells that survive this immune response, now called B blasts, 
migrate to the germinal centre (GC) – becoming centroblasts – and switch to a default 
programme called latency II. In this stage, expression of membrane proteins of the virus, 
LMP1 and LMP2, mimic the antigen and survival signals from Th cells, required for the the B 
cell to survive pro-apoptotic signals in the GC. B cells therefore become activated and 
proliferate, finally differentiating in plasma cells or memory B cells. Memory B cells can 
undergo sporadic homeostatic division, and the EBV-infected ones can suffer occasional lytic 
reactivation. 
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 In dividing memory B cells, only EBNA-1 is expressed, in order to preserve the viral 
episome in a latency I profile. The resting memory B cells are the only ones in a “true 
latency” profile (latency 0), in which no viral genes are expressed, only some of the micro-














Figure 1.1: Schematic representation of the hijacking of the B cells  by EBV to fulfil its own life cycle inside the 
host; the blue circle within the cells represents the viral episome; the titles in yellow refer to alternative names 
for the viral gene expression stages: growth refers to the latency III gene expression, default is also known as 
latency II, latency refers to the stage of latency 0, where no genes are expressed, while EBNA-1 expression 
occurs during the so-called latency I. Lytic re-activation can occur, producing virions that re-infect other naïve 
B cells or are shed in the saliva, infected new hosts (Münz 2015).	
The viral particles are produced through the lytic replication cycle, and transmitted in 
saliva during the initial infection or after spontaneous reactivation. Studies point that rare 
spontaneous reactivation of latency III infected B cells is likely to be related to cellular factors 
(Davies et al. 2010).  A simplified way to look at the EBV life cycle inside the human body is 
as a progressive shutdown process, that accompanies the B cell natural maturation process, 
with the virus reducing its genetic expression stage by stage and thus maximizing the 
probability of remaining within its host cells as a silent parasite. Other herpesviruses have 
evolved to replicate in growth arrested cells, like cytomegalovirus (CMV) or herpesvirus 











lytic reactivation in epithelial or fibroblast cells (Damania 2004). Unlike CMV and HSV that 
in certain cell types can go directly to lytic replication, so far EBV has been shown to need a 
latency stage and exposure to lytic activation stimuli to start viral replication (Flemington 
2001).  For this reason, EBV produces early lytic gene products capable of arresting cell-
growth in a G0 or G1 stage after reactivation from latency, while the CMV and HSV produce 
analogue products during primary infection. The purpose of the induction and/or maintenance 
of the cell cycle arrest during the viral lytic phase is possibly to avoid competition for 
nucleotide resources when the cell DNA replication takes place, in the S phase (Flemington 
2001). Apart from the cell cycle arrest, all of these herpesviruses produce proteins capable of 
activating pathways that mimic cell cycle entry or allow for a partial cell cycle progression, 
meaning they evolved a very fine tuning system to allow for better replication conditions. 
1.3 Oncogenic processes in EBV positive cells 
 
EBV’s ability to prevent apoptosis and drive proliferation of cells, works in a different 
way depending on the differentiation state of the host cell. In spite of its capacity to induce 
cell proliferation (latency III), this transcriptional state is not found in all EBV-associated 
cancers. This is because in healthy carriers, B cells expressing the viral full growth 
programme, are easily recognized and destroyed by cytotoxic T cells (Klein et al. 2007). 
So what are the causal relations between EBV infection of B lymphocytes and some 
types of lymphomas? Immediately after EBV infects naïve B cells, it starts expressing 
proliferation latency III genes; in healthy carriers the control of the gene expression, as 
mentioned before, is assured by the T cell response, which deletes the viruses that didn’t start 
the transcription silencing process. If the latency III infected cells are for some reason unable 
to leave the cell cycle, and the carrier is immunosuppressed, they can continue proliferating 
and this might lead to the development of immunoblastic lymphomas, such as post-transplant 
lymphoproliferative disease (PTLD) (Klein et al. 2007), AIDS–associated lymphomas	(Münz 
2015), or diffuse large B cell lymphoma (DLBCL) of the elderly.  
B cells are created in the bone marrow and they enter the circulation as naïve B cells, 
because they haven’t been activated by an Ag yet; cells in this stage only last few days in 
circulation before being eliminated, which happens to the vast majority. Migration to the 
Germinal Centre in the lymph nodes takes place, and if they recognize an Ag that binds their 
BCR (B Cell Receptor), the Ag is internalized, processed and expressed at the surface of the 
cell associated to MHC II (Major Histocompatibility Complex Class II) molecules; 
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simultaneously, dendritic cells also migrate to the lymph nodes and present the Ag to T cells, 
that is recognized by the TCR  (T Cell Receptor) receptor and makes the T cells migrate to the 
B cell area of the lymph node. When the activated T cell gets there, it recognizes the Ag being 
expressed at the surface of the B cell, via the TCR and releases IL-4, that activates the B cell, 
causing the B cell receptor B7 to bind the CD28 receptor in the T cell; the binding of the 
receptors causes CD40L to be upregulated at the surface of the T cell and the binding to the 
CD40 in the B cell to occur. This final signal tells the B cell to proliferate and differentiate in 
either a plasma Ab-secreating cell or a memory cell (Kurosaki et al. 2015).  
EBV-activated B cells also migrate to the germinal centre, but in contrast they do not 
require the CD40 or BCR signalling. Instead, LMP1 and LMP2A act as constitutively active 
signalling molecules, sending the same signals as activated CD40 and BCR, allowing the 
survival of the B cell in the absence of antigen-associated T cell help.  
Hodgkin Lymphoma arises from EBV latency II infected B cells, most of the EBV 
positive cases being characterized by a crippling mutation in the immunoglobulin genes, that 
should in normal cases conduct the cell to an apoptotic pathway; instead because of the virus 
expression of the LMPs, the BCR signal is replaced by LMP2A signalling, and rescue signals 
are given by LMP1, causing the rescuing of the crippled cell and allowing it to continue the 
maturation process (Bechtel 2005; Chaganti 2005; Mancao 2005). Burkitt Lymphoma (BL), 
usually manifests from cells in the memory compartment or late GC cells. The genetic mark 
of this disease is a translocation of the myc oncogene with a highly expressed locus, usually 
one of the immunoglobulin genes, that deregulates the activity of the former. In this case, the 
EBV effect in the cell might be related to limiting its sensitivity to apoptosis in two stages: 
before entering in the germinal centre, the latency III program epigenetically silences the bim 
and p16INK4A regulators of apoptosis (Paschos et al. 2012).  Once through the GC, the latency I 
profile found in BL expresses the viral EBERs, microRNAs and EBNA-1, which may render 
the cell more resistant to apoptosis and senescence (Allday 2009; Klein et al. 2007). 
1.4 Genetic Regulation of the EBV genes  
	
In latency III, the six EBNAs are spliced from a long primary transcript (Speck & 
Strominger 1985), initiated either from the Wp or the Cp promoters (figure 1.2). EBNA-LP, 
the first protein to be encoded by the polycistronic transcript (hence leader protein), is 
encoded across a tandem repeat region of the genome (the Bam W repeats), each of the W 
repeats containing a Wp promoter. Transcription from the Wp promoters occurs 
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predominantly in early B cell infection, since it is the first promoter to be activated after 
infection. Wp gives rise to high numbers of copies of EBNA-2 and different sized EBNA-LP 
proteins, depending on which Wp is used to make the transcript (Finke et al. 1987). As soon 
as these proteins start regulating other viral genes, the use of Wp promoters starts decreasing 
and is progressively replaced by transcription from the Cp promoter, that is already 
predominant by day 4 post-infection. The Cp promoter becomes activated by EBNA-2 and 













Figure 1.2: Structure of the EBV episome, emphasizing the position of the latency associated promoters (in red) 
and genes (Young & Rickinson 2004). 
 In latency III, expression of the LMP promoters is also upregulated by EBNA-2, that 
acts as a co-factor interacting with the RBP-Jk and PU.1 transcription factors of the ED L1 
promoter. In latency II however, activation of the upstream promoter TR L1 is EBNA-2 
independent, and depends instead on interleukins that interfere with the JAK/STAT pathways, 
or as more recently described, on the C/EBP (Noda et al. 2011).  
It has been shown that the control of the Wp to Cp promoter switch is mostly regulated by 
methylation (Jansson et al. 1992; Hutchings et al. 2006), although recent studies seem to point 
IL-21 as a potential inhibitor of the transactivation function of EBNA-2, being able to 
decrease the Cp and LMP2A derived mRNAs and increase Qp transcription (Kis et al. 2010).  
In latency I, the Qp promoter takes the place of Cp, allowing only for the translation of 
EBNA-1 mRNA (Nonkwelo et al. 1996).  
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1.5 Ability to induce B cell immortalization: in vitro generation of LCLs 
 
It was first described in 1989, the EBV latency III profile in vitro ability to prevent 
apoptosis and trigger proliferation of B cells, turning them into lymphoblastic cell lines 
(LCLs) that resemble the ones present in PTLD cells (Hammerschmidt & Sugden 1989). For 
this process to take place several genes are required, like EBNA-2 and LMP1. It is important 
to mention that LCLs are not necessarily immortal cell lines: according to Sugimoto et al. 
(2006), immortalized cells present a strong up regulation of telomerase activity, an abnormal 
karyotype and Population Doubling Levels (PDL) above 160; thus, they also conclude that 
90% of normal LCLs are not immortal, once they lack the first two requirements and present 
a mean PDL of 92-94 before they encounter a growth crisis that is only overcome if the cells 
develop a mutation to prevent the shortening of the telomeres. 
LCLs are mostly Cp transcription-based, although expression from the Wp is still 
present (Li & Minarovits 2003; Hutchings et al. 2006). EBNA-2 promotes the activation of 
the Cp promoter and the LMP1, LMP2B bidirectional promoter, with the help of EBNA-LP 
(Peng et al. 2005; McCann et al. 2001). It also activates transcription of cellular genes, by 
interaction with the DNA-binding proteins such as RPB-Jk (Henkel et al. 1994) and EBF1. 
According to Lu et al. (2016), EBNA-2 drives the formation of chromosomal occupancy sites 
for RPB-Jk and EBF1 activating transcription functions by increasing the stability and 
probability of binding and forming enhancer-promoter loop interactions. EBNA-2 can also 
directly bind Pu.1: this is another essential interaction to co-activate LMP1 (Johannsen et al. 
1995). One of the main functions attributed to EBNA-2 is the activation of the MYC proto-
oncogene (Jayachandra et al. 1999); that activation is also thought to lead to the induction of 
cyclin D2, driving the cells to proliferate (Spender et al. 2001). Besides the activation of viral 
promoters,  cellular targets of EBNA-2 include CD21, CD23 and c-fgr (Kiermaier et al. 
1999).  
LMP1, by mimicking the CD40 B cell receptor, is able to activate signalling 
pathways, to supress cell death by up-regulation of anti-apoptotic proteins and to interfere 
with the machinery regulating cellular senescence. In EBV positive carcinomas, it may also 
influence angiogenesis and promote metastasisis (reviewed in (Eliopoulos & Young 2001)). 
EBNA-3A and -3C co-operate to repress the transcription of p16INK4A (Skalska et al. 2013) – 
an important cell cycle regulator – and BIM (Paschos et al. 2012), a pro-apoptotic factor. 
These two genes prevent cell apoptosis. A study shows that EBNA-3B, on the other hand, 
behaves like a viral encoded tumour suppressor, restraining the proliferation of EBV-
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transformed B cells and allowing them to attract T lymphocytes via chemokine secretion. 
Probably this represents a strategy of the virus to preserve chronic viral infection without the 
severe morbidity and mortality caused by oncogenic outcomes of the infection (White et al. 
2012). These genes are mostly important from day 14 after infection. 
Because of its repetitive nature, the role of EBNA-LP has been poorly studied in the 
past. Evidence showed that though the protein is not essential for transformation, although its 
absence substantially diminishes the viral transformation efficiency, demanding co-cultivation 
with feeder cells in order to re-establish the original efficiency (Mannick et al. 1991).  This 
observation might be related to its role as a co-factor of EBNA-2 in promoting transcription 
of EBNA-2 targets genes, such as LMP1 (Peng et al. 2005), although it is likely that EBNA-
LP interacts also with other factors in regulating B cell transformation. LP as also been shown 
to co-operate with EBNA-2 in the control of cell cycle regulation (Sinclair et al. 1994). 
Along with the latency III transcripts, the BHRF1 microRNA cluster is also expressed 
and important for the beginning of transformation, given that it favours cell cycle progression 
and proliferation during early B cell infection (Seto et al. 2010; Haar et al. 2016). A different 
microRNA cluster, the BART miRNA, has recently been studied; the upregulation of the 
cluster as a whole can provide a significant growth advantage to infected tumour cells in an 
animal model, possibly due to growth promoting and survival functions, although the same 
effect hasn’t been seen in vitro (Qiu et al. 2015). 
1.6 Splicing events in latency III infected B cells  
 
EBNA-LP is encoded by exons W1 and W2, present in the W repeats downstream 
from the Cp promoter. Each repeat unit contains a W1 and a W2 exon (Speck et al. 1986) 
while the stop codon for LP is in the exon Y2, present in the unique region downstream of of 
the repeats.  The EBNA-2 reading frame is present in a third Y exon. Alternative transcription 
of EBNA-LP or EBNA-2 from either the Cp or Wp is defined by one of the two alternative 
splice donors (C2 or W0 respectively) used to link the promoter exon to the coding exons 
(figure 3.i). When the W0 or C2 exon splices to the W1’ exon, an ATG start codon forms 
across the splice junction. This is the initiation codon for EBNA-LP, allowing for the protein 
to be translated from the subsequent array of W1 and W2 exons and the Y1 and Y2 unique 
exons. Alternatively, when W0 or C2 splices to the W1 exon instead, the start codon does not 
form: in this case the first starting codon will be in the exon YH originating EBNA-2 
	 9	
transcripts. Similarly, when the promoter Cp is in use, exon C2 can splice to either one of the 
W1 exons, with the same results as for the Wp promoter (Rogers et al. 1990).  
 As for the splicing of the Y2 or Y3 donors, they can splice to a region downstream, to 
exon U, that contains an internal ribosome entry site (figure 1.3.ii) or if the splicing fails, YH 
exon containing the EBNA-2 ORF is maintained. Splicing to U allows for the translation of 
the EBNA-3s and EBNA-1. The alternative splice junctions between U and the EBNA-3 
coding exons define the transcribed protein (figure 1.3.iii). 
Figure 1.3: EBNA-LP is encoded by codons W1 and W2 present in the repeated region W. Different length 
EBNA-LP proteins can be produced depending on the promoter used; by an alternative splicing process the 
virus is able to regulate if either EBNA-LP or EBNA-2 are produced from the Wp and the Cp; splicing junctions 
define the protein products of the polycistronic transcript (Allday et al. 2015).  
Some of the introns excised during splicing accumulate in cells, and perform regulatory 
roles as non-coding RNAs of different types. The subject of the present project is precisely 
two of these introns from EBV, the one excised between the W1-W2 exons, named EBV 
sisRNA-1 and the one between W2 exon and the W1 exon of the subsequent W repeat, called 
EBV sisRNA-2. Stable Intronic sequence RNAs (sisRNAs) will be defined and described 
further in the next sections. 
 
1.7 Non-coding RNAs in viruses 
	
Until recently, the only widely-known non-coding RNAs (ncRNAs) in eukaryotes  
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were tRNA and rRNA involved in the translation of proteins from mRNA. Now we also know 
small nuclear RNAs (snRNAs) involved in splicing and small nucleolar RNAs (snoRNAs) 
involved in the modification of rRNAs. And these are just examples of the important roles 
ncRNAs can have. In humans for instance, other forms of ncRNA were shown to be involved 
in the control of chromosome dynamics, splicing, RNA editing and mRNA destruction, as 
well as gene regulation and inhibition of translation (Mattick 2006).  
Some viruses, similarly to eukaryotic cells, can express ncRNAs. The fact that viruses 
have limited space in their genome to fit useless genetic material suggests that the ncRNAs 
they carry and transcribe, play some type of important role in manipulation of the host cell, 
such as helping infection or protecting against host immunity. Because intracellular RNA not 
immunogenic, contrary to proteins (at least at the level of triggering an adaptive immune 
response), using RNA rather than proteins can be an alternative way for the virus to 
manipulate host cells with less likelihood of triggering an immune response (Tycowski et al. 
2015a). Viral ncRNAs have been regarded as a valuable tool not only for the study of the 
virus biology but also to gain insides in the host cell regulation, once the mechanisms used by 
both might be similar. 	
Viral ncRNA transcribed by polymerase III (VA ncRNAs) were the first viral ncRNAs 
to be identified, and they are related to the action against the host antiviral defences 
specifically through inhibition of Protein Kinase R (PKR); this type of pol III ncRNA is find 
in Adenoviruses, where it competes with the viral-synthesized dsDNA for the binding of the 
PKR, blocking it from being activated (Wilson et al. 2014).  
The EBERs – EBV Encoded RNAs – are analogues of the VA ncRNA. EBERs  1 and 
2 reside in the nucleoplasm, where they accumulate to very high levels (106 molecules/ 
infected B cell for EBER1 and 2.5x105 for EBER2) (reviewed in (Tycowski et al. 2015b). 
Both EBERs seem to be similar in function to the VA ncRNAs, because they are both 
highly structured, polymerase III transcribed, and bind to the La factor (Lerner & Steitz 
1981), a cellular chaperone that recognizes the U-rich 3’ end of all pol III transcripts, possibly 
having a host-repression role of the antiviral response. The complex EBER1 forms with La 
was found to extracellularly activate the Toll-Like Receptor 3. EBER1 was also described to 
bind the L22 ribosomal protein (Toczyski & Steitz 1991), causing it to be shuttle from the 
nucleolus to the nucleoplasm and to bind the AU-rich element-binding factor 1 
(AUF1/heterogeneous nuclear ribonucleoprotein D [hnRNPD]) (Toczyski & Steitz 1991). Lee 
et al. (2012) proposed that sequestering of AUF1 by EBER1 leads to interference with the 
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AUF1 normal functions, such as regulating the stability of AU-rich element-containing 
mRNAs or suppressing senescence and maintaining telomeres.  
More recently, EBER2 was found to bind to nascent transcripts from the terminal 
repeats (TR) of EBV in a place that overlaps with a PAX5 binding site, which together 
regulate the expression of a subset of viral latent products (Lee et al. 2015). The role of the 
ncRNA in this case seems to be to guide the recruitment or stabilization of the PAX5 cellular 
factor, compromising the viral lytic replication of the virus. 
MicroRNAs are defined as small ncRNAs, 21-25 nucleotides long, that bind to mRNA 
transcripts and abrogate their protein coding functions (Seto et al. 2010). As previously 
mentioned the EBV genome, encodes several microRNAs (miRs), focused in two clusters: the 
BART and the BHRF1 microRNAs. Also, a viral small nucleolar RNA (snoRNA) is 
processed from the BART introns during the viral lytic reactivation, and targets the 3’ UTR of 
the BALF5 (viral polymerase) mRNA, which might implicate some type of transcriptional 
regulation role.  
 HSV, another gamma-herpesvirus, encodes Herpesvirus Saimiri U RNAs (HSURs), 
ncRNAs that resemble snRNAs: cells infected with viruses that lack HSUR 1 and 2 (which 
are between 114 nt-143 nt long) grow significantly slower than WT (Murthy et al. 1989), 
showing the genetic element’s ability of aiding the T cell transformation process. A 
microarray analysis later showed that the host genes involved in T cell activation are up 
regulated by the mentioned ncRNAs (Cook et al. 2005); furthermore, they also interact with 
the host’s microRNAs (Cazalla et al. 2010), specifically targeting one of them – miR-27 – for 
degradation. This host miRNA is a repressor of the T cell activation, so by degrading it, 
activation and proliferation of the host cells is achieved by the virus. Murine Cytomegalovirus 
(MCMV), a beta-herpesvirus promotes the same targeting of miR-27 mediated by an 
antisense-RNA based mechanism (Buck et al. 2010); it also expresses sisRNAs, of unknown 
function (Kulesza & Shenk 2006).   
All of these examples illustrate the various roles ncRNAs can have in viruses. 
 
1.8 SisRNAs found in W repeats of EBV 
	
Herpesviruses are the viral family that accumulated the widest variety of ncRNA, maybe due 
to their long latent infection and genetic exchange with the host cell and to the big genomes 
(Tycowski et al. 2015). The most well described (and still with a lot to understand) of the 
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class of the sisRNAs is the LAT intron of the alpha-herpesvirus HSV-1, that contributes to the 
stabilization of heterochromatin at the promoters of viral lytic genes  (by mechanisms that 
remain unclear) silencing viral gene expression and promoting viral latency (Hesselberth 
2013).  The LAT transcript is about 8.3 Kb long, capped and polyadenylated and it is spliced 
in a 6.3 Kb exon and a 2 Kb intron; the exonic sequence is further processed to generate four 
viral miRNAs (Umbach et al. 2008) as well as two small RNAs (62 nt and 36 nt). More 
recently, HCMV was also found to produce an early sisRNA (Kulesza & Shenk 2004), and a 
similar MCMV sisRNA was discovered  that seems to be an essential virulence factor in vivo, 
being required for the progression from an acute to persistent infection; it is about 7.2 Kb 
long. 
EBV has a complex transcriptome, where several pre-mRNA transcripts undergo 
alternative splicing events and promoter switching, producing different gene products 
depending on the stage of the infection and state of the host cell (see figure 1.3 and section 
1.1.6). Moss and Steitz (2013) discovered EBV’s first sisRNAs after deep sequencing, shown 
by the presence of large peaks within the W repeat region. One peak covered the small intron 
that separates the W1 and W2 exons. Other peaks were found in the much larger intron 
separating Exon W2 from the W1 exon of the next repeat unit. The region between the two 
genes is spliced in latency III, to allow the W exons to be transcribed (Rogers et al. 1990). It 
gives rise to long (2791 nt) and short (81 nt) introns, from which the long intron is predicted 
to be 49 % covered by a conserved and stable RNA structure (see figure 1.5 for the position 
of the sisRNAs).  
sisRNA-1 (the name given to the shorter of the introns) is the most abundant viral 
RNA in latently infected cells after EBER1 and EBER2 detected in an RNA-seq library built 
from nuclear RNA from cultured	BJAB cells (B lymphocytes), stably infected with EBV. It is 
most abundant in the nucleus when compared to the cytoplasm. Furthermore, its presence in 
the cell was shown by Northen blot. The sisRNA-1 nucleotide sequence is 100% conserved 
through at least 76 EBV strains (Ba Abdullah, unpublished), and presented similarities with 
similar structures in other Lymphocryptoviruses (Moss & Steitz 2013).  
Its predicted structure includes two small hairpins (figure 1.4); an upstream 23 nt one 
that comprises a U-rich loop and a downstream weaker one (though more recent articles seem 
to cast doubt on this weaker feature: see (Moss et al. 2014), that forms a CA–rich loop. Base-
pairing in the first is preserved by compensatory mutations between different 
lymphocryptovirus species, implying a functional importance. The presence of this loop 
structure might indicate a protein-interacting role for sisRNA-1, since U-rich short regions 
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 were long described to bind proteins (You et al. 1992) and hairpins can prepare RNA for 
interaction with proteins; in addiction CA-rich regions are able to bind hnRNP L and 
modulate splicing (Hui et al. 2005). 
Figure 1.4- Predicted structure of the sisRNA-1 includes a hairpin  in a UA rich region; the red arrows  in the 
lined  sequences show the compensatory mutations in positions 8 e 23 of CaHV3 that preserve base-pairing and  
this structure, (signalled in the predicted structure in red)  in other viruses of the same family, suggesting an 
important role to the hairpin; adapted from (Moss & Steitz 2013). 
 
EBV sisRNA-2 (the longer intron), appears to include a structure with a very long 
(586 nt) hairpin, similar to others found in three other lymphocryptovirus species within 
repeated regions homologous to the EBV W repeats. The highly thermodynamically stable 
sequence as well as the conservation of the sequence within the hairpin in several EBV strains 
seems to indicate that evolution is acting to preserve this structure. The presence of such a big 
stem-loop is rare in viruses, but it is found in humans and some protozoa, as structures that 
are good substrates for adenosine deaminase RNA editing enzymes (ADARs), and there is 
previous evidence of RNA editing in transcripts of the hairpin of EBV (Arvey et al. 2012). 
1.9 Previous evidence for the importance of EBV sisRNAs in B cell infection 
	
Previous studies of the White laboratory in Imperial College London Section of  
Virology at St Mary’s Hospital, have shown evidence that mutations in the EBV sisRNAs 
regions might comprise the virus’ ability to transform B cells.  
A panel of EBNA-LP knockout (LPKOi) and revertant (LPrevi) viruses were 
generated by Agniezska Szymula (dissertation, 2016) to study the potential effects of 
knocking out the EBNA-LP protein by inserting a stop codon in all W1 exons of the BamW 
repeat, or by deleting the Y exons of the unique region downstream of the W repeats. A Cell 
proliferation assay was set up using the generated mutants along with previously created WT.  
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The cloning strategy used to create a full EBNA-LP KO, comprised the subcloning 
and modification of one of the W repeats from the B95-8 virus genome (used as the prototype 
strain for EBV type 1). Six of these mutated repeat units were assembled, generating a full 
tandem region with homogeneous mutant repeats. This was inserted into an EBV BAC from 
which the W repeats had been deleted (WKO). This way, a virus possessing 6 W repeats – all 
mutated – was assembled. A revertant of this LPKO was then made by deleting the mutant 













The first generation of mutants created was identified as LPKOi and LPrevi since after 
sequencing of the W repeat from HB9 used to build both the recombinant viruses, three 
single-point mutations (or SNPs) were found within the BWRF1 ORF (a predicted open 
reading frame with no start codon of unknown function) that lies within the sisRNA-2 region. 
These variants (as well as a STOP codon in exon W1, which is not in the recombinants) are 
found in one repeat within the parental B95-8 strain of EBV. Two of these mutations might be 
minor variants, because they were found in other EBV strands (Ba Abdullah and White – 
unpublished) Additionally, as part of the cloning strategy, a point mutation was also 
introduced into an existing BsmBI restriction site, between exons W1 and W2, in the region 
later identified as the sisRNA-1 region (figure 1.5). The use of this mutated W repeat from a 
supposedly WT virus and the cloning strategy used, resulted in the introduction of these 
mutations in all of the repeats. 
By day 7 after infection, both the EBNA-LP WT, EBNA-2rev and Yrev had caused 
the infected cells to undergo several rounds of cell division, while proliferation of LPKOi-
infected cells was very poor. However, the LPrevi was much less efficient at driving 
proliferation, when it should be expected to behave similarly to the WT virus (figure 1.6). 
sisRNA-1														 sisRNA-2														
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A second generation of recombinants was then made to verify if the same conclusions 
were valid for true LPKO mutants, and also to compare if the mutations in the sis regions had 
the effects observed in the 1st generation. Both the new LPrevw and LPKOw were generated 
by creating a new WT array with a repeat that was sequenced and they did not present any 
intronic variations. For the LPKO a mutation was inserted in all of the repeats and assembled 
into the array afterwards. These ‘w’ viruses were better at driving the proliferation of the 
infected cell than the ‘i’ viruses (figure 1.6). Therefore, the intronic mutations seem to have a 
detrimental effect on proliferation. 
A. Szymula has shown that the transcription and splicing in the LCLs generated with 
the mutated viruses was not affected (Szymula, dissertation 2016) but LPrevi viruses shown 
an elevated LMP1 expression by day 30 and a difference in the usage of Wp promoter, which 
is 4 times higher than for other viruses by day 30. Contrary to other infections, the usage of 
Wp starts increasing significantly between day 9- 16 for the revi viruses. 
 
	
Figure 1.6- Proliferation assays performed by A. Szymula (dissertation 2016); on the x-axis the dilution of the 
nuclear dye Cell Trace Violet indicates the degree of proliferation, once the dye gets more diluted every time 
cells divide; on the Y axis the number of events detected (number of cells) by day 7 post-infection EBNA-2 and 
Y1Y2 revertants enter hyperproliferation, while LP and Y1Y2 KO are impaired; strangely, LPrevi presents and 
impaired proliferation when compared with the other WT and Revs. 
The fact that the sisRNA structures are so conserved among gamma-herpesviruses, 
and that other viruses have been shown to generate sisRNA with important regulatory roles, 
suggests that either the mutations on the sisRNA-1 or -2 are responsible for the observed 
phenotype. 
UNINFECTED EBNA-2KO LPKOi	2.6 Y1Y1KO	4.21 
WTi EBNA-2rev LPrevi	2.6 Y1Y2rev	4.21 
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1.10 Aims and hypothesis 
 
The hypotheses on which the work will be based are very general, given that little is 
known on the role of the sisRNAs, especially when looking at sisRNA-1, that is unusually 
small for a sisRNA. Given this, the hypotheses will be the following: 
1st : the sisRNA-1 mutation is responsible for the LPrevi transformation defect, not the 
BWRF1 mutations  
2nd : sisRNA-1 is playing a  role in the regulation of LMP1 transcripts and Cp/Wp ratio (based 
on Agnieszka’s preliminary results). 
These hypotheses will be tested in the following way: 
1st : By cloning the BsmBI mutation (sisRNA-1), BWRF1 variants (triple mutation) and a 
complete deletion of sisRNA-1 into three independent mutants. Viruses will be produced and 
their transformation efficiency will be accessed by outgrowth observations and cell trace 
experiments. 
2nd : The role of the sisRNA-1 in regulation transcription will be determined by qPCR of 
infections with the above mutants, looking at transcript levels from each promoter. 
After generating the BACs, transfection into HEK 293-SL cell lines will allow for the 
creation of viral-producing cell lines that will be induced to enter the lytic cycle and therefore, 
to produce viruses. These viruses will be used to infect PBLs and isolated B cells from buffy 
coats. Early infection studies in B cells will be performed to observe phenotypic changes 
(specifically delay or incapability to produce LCLs), and RNA studies on targets namely 
LMP1, EBNA-2 and transcripts from the different latency associated promoters will be 









Chapter 2 : Materials and Methods 
	
Reagents and Solutions note: All of the reagents and solutions used in the protocols have their 
composition described in Appendix I. Appendix II contains the stock and working 
concentration of the antibodies used in Western Blotting and the sequence of all the primers 
used. 
2.1 DNA Manipulation and Cloning 
 
2.1.1 Preparative DNA digests: Mix was prepared with 1 µg of DNA, 3 µl of 10 x Enzyme 
Buffer, 3 U of enzyme (0.3 µl), 22 µl ddH20, digested at the appropriate temperature between 
1.30 h and 3 h and inactivated at appropriate temperature for 20 min when required by the 
enzyme (Enzymes New England Biolabs). 
2.1.2 DNA extraction from agarose gel of fragments up to 20 Kb in size: Qiaquick Gel 
Extraction Kit (Qiagen, cat 28706) using spin columns according to the manufacturer’s 
protocol. 
2.1.3 DNA extraction from agarose gel of fragments more then 20 Kb: Qiaex II Gel 
Extraction Kit (Qiagen, cat 20021), using manufacturer’s protocol for DNA extraction from 
agarose gels using beads. 
2.1.4 DNA ligation: Using the T4 DNA Ligase kit (New England Biolabs) mix was prepared 
in a final volume of 10 µl, using 1 µl 10 x T4 ligase Buffer, ~ 0.3 µl T4 ligase enzyme per 
reaction 1:3, 1:6 or 1:9 vector to insert molar ratio, depending on the size of the insert. 
Incubation for 2-3 h at RT. 
2.1.5 Transformation of competent bacteria: 50 µl of competent bacteria (DH5 alpha strain 
of E. coli) were added to a pre-cooled tube containing the ligation reagents as described 
above, left in ice for 30 min, heat-shocked at 42 ºC for 1 min in a water bath, and cooled in 
ice for 1-2 min; 1 ml of LB was then added to the tube and transformation recovery was done 
at 37 ºC for 1 h (or 30 ºC for 1.30 h) before plating. 
2.1.6 Plasmid DNA mini-prep: Cells were pelleted and then resuspended in 70 µl of STET; 
bacterial lysis was induced by adding 200 µl of alkaline SDS and neutralised by adding 150 
µl of ammonium acetate 7.5 M immediately after, all while vortexing the sample. The cells 
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were incubated with lysis buffer for 15 min in ice and then centrifuged at 13000 rpm at 4 ºC 
for 15 min. The plasmid DNA was precipitated by adding 240 µl of isopropanol to the 
supernatant and pelleted by centrifugation at 10000 rpm for 5 min at RT. The pellet was 
washed with 200 µl of 70 % ethanol. After air-drying for 15 min, DNA was resuspended in 50 
µl of TE supplemented with 5 µg/ml RNAse (Qiagen).  
2.1.7 Diagnostic DNA digests: Mix was prepared with 1-5 µl of DNA (1 µl of conventional 
plasmids, 2 µl of pKovKan-based plasmids and 5 µl of BAC mini-preps), 1.5 µl of 10 x 
enzyme Buffer, 0.3 µl enzyme, made up to 15 µl ddH20 and incubated from 1.30 h to 3 h 
hours.  
2.1.8 Gel electrophoresis: Gels were prepared in 1x TBE using agarose at 1 % and run in 1 x 
TBE buffer at 80-85 V for the required time. 
2.1.9 DNA sequencing: Mini-prep DNA was purified using Zymoclean Gel DNA Recovery 
Kit (Zymo Research, cat D4008); each sequencing reaction was prepared in 10 µl total 
volume containing 3.2 pmole of primers and 2-3 µg of genomic DNA.  Samples were send to 
the MCR genomics core laboratory (Hammersmith Hospital, London) for sequencing. 
2.1.10 Overview of recombinant BAC generation: The recombinant BACs were produced 
using a combination of cloning, Gibson Assembly and Recombineering (i.e. RecA-mediated 
homologous recombination) techniques. Each final BAC contained 6 identical W repeat units, 
each carrying the desired mutation. The cloning strategy used included the cloning of the 
desired mutations into five constructs, with each containing a single repeat unit in a different 
restriction enzyme a specific Amp vector. These were combined in sets of three repeats using 
Gibson assembly to make two constructs: three to make the C exon extremity of the repeats 
and three others to make the Y exons extremity (figure 2.1). After this stage both assembled 
constructs were joined together by Gibson Assembly (figure 2.2) and the resulting 6 repeat 
construct was cloned into a shuttle plasmid (pKovKan) carrying a kanamycin resistance gene 
(KanR) that also contained a temperature sensitive origin of replication,  and a SacBII gene 
that confers sensitivity to sucrose for negative selection (figure 2.3). 
The resulting construct was then recombined into an EBV-BAC by RecA mediated 
recombination in bacteria. The resulting co-integrants were resolved by making the cells 
carrying the recombined EBV BAC competent, and transforming again with the RecA-











Figure 2.1: Gibson Assembly was used to assemble the mutated repeats in two groups of three repeats each; pA 
contains the C exon for the homologous recombination into the EBV genome while pB contains the exons Y (Y1 
and Y2), both represented in blue, the red bars represent the mutated region in each repeat, parental plasmids 
used in the cloning strategy are emphasised as well as the restriction enzymes used to digest the extremities of 
each plasmid  in order to make it possible to assemble them in a specific order and orientation based on their 
overlapping homology. 
	








Figure 2.3: Example of a pKov-Kan-based vector containing an array of 6 W repeats. Note the C2 exon and the 
Y1 and Y2 exons flanking the repeated region, which indicate the positions of homology regions; notice the Kan 
resistance and SACBII genes from the KovKan backbone used for the selection of the plasmid; the restriction 
enzyme cutting sites represented (HindIII; SalI; NotI) were used for diagnostic digestions. 
	
2.1.11 Gibson Assembly: This DNA cloning protocol allows for the combination of several 
fragments simultaneously in the same reaction tube, creating a product with no restriction site 
scarring. Using the NE Builder HiFi DNA Assembly Master Mix (New England Biolabs). For 
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assembly of 2 fragments ratio was kept at 2:1 insert to vector even when it caused the amount 
of vector to be reduced to around 25 ng instead of the recommended 50 ng; for assembly of 3 
fragments, the insert to vector ratio was kept at 6:6:1. Incubation in the thermo cycler was 
performed at 50 ºC for 45 min. 
 
2.1.12 Recombineering: This method was originated by Lalioti and Heath (2001) and 
modified in White, Calderwood and Whitehouse (2003). It requires 250-700 bp homology 
regions flanking the change. The most important stages of the process are represented in 
figure 2.4 below. 
 
a) Co-Transformation with pKov-KanDCm and pDF25-tet: Miniprep DNA of the 6 repeat 
product (3-5 µl) was used alongside 1 µl of the RecA-expressing pDF25-tet to co-transform 
the DH10B strain of E.coli (Life Technologies), containing pHB9-WKO+4.9 (W4 for short), 
a BAC containing the cloned genome of EBV strain B95-8 from which the whole W repeat 
sequence was deleted. The plasmid producing RecA promotes homologous recombination 
between the C or Y regions of the targeting construct and the EBV-BAC, introducing the 
pKovKan plasmid containing the mutated repeats into the EBV-BAC plasmid. 
Transformation was done as described above, and bacterial recovery was done at 30 ºC for	
1.30 h due to the temperature sensitive replication origin of the mutants. The co-transformed 
bacteria were then grown in plates with Kan, Cm and Tet, O/N at 30 ºC, to select for bacteria 
containing both plasmids and the EBV-BAC. The next day, pools of colonies were picked 
into 1 ml of LB and 100 µl of this culture were immediately plated in Cm+Kan plates and 
incubated O/N at 43 ºC. This is to select for WKO BACs that had recombined with the 
pKovKan plasmid; loss of un-recombined pKovKan and pDFtet carrying bacteria was 
ensured by their temperature sensitive replication origins, which are not active at 43 ºC.  
b) Co-integrant testing: Next day colonies were picked into 1.5 ml of SB and grown O/N at 
37 ºC. BAC DNA was isolated by mini-prep and analysed using restriction enzyme digestion 
and pulsed field gel electrophoresis. Since valid recombinants could be generated by 
recombination with either of the two half-sites of homology, both types of recombinants were 
distinguished and used to make competent bacteria for the next step (resolving of the co-
integrants).  
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c) Making competent co-integrants: The tubes used to grow the bacteria for mini-prep in 
the previous step were kept, 1.5 ml of LB agar with Kan+Cm was added and incubated O/N 
again at 43 ºC. The next day, 100 µl of this culture were diluted into 10 ml of LB with 
Kan+Cm and grown for 3 h at 37 ºC . The cultures were placed on ice for 30 min in the cold 
room and then centrifuged at 4000 rpm, 4 ºC for 15 min. In the cold room, the media was 
removed, cells were resuspended in 2 ml of 100 mM CaCl2 and left on ice for 30 min. Cells 
were again centrifuged at the same speed and temperature and resuspended in 200 µl of 100 
mM CaCl2 with 15 % glycerol. Aliquots of 50 µl were frozen at -80 ºC.  
d) Resolving the co-integrants: In the next morning, 50 µl of competent co-integrants were 
transformed with 0.5 µl of pDF25-tet maxi-prep as before, plated on LB agar plates 
containing Cm+Tet and incubated O/N at 30 ºC. The next morning, pools of colonies were 
picked into 1 ml of LB + 5% sucrose+Cm+Tet and left to incubate for ~ 8 hours at 30 ºC 
before streaking (with progressive dilution) 20 µl of this onto a 14 cm LB agar plate 
containing 5% sucrose and Cm, and incubating O/N at 43 ºC. The next morning isolated 
colonies were picked and 2 µl of each were plated in Cm+Kan plates and Cm only plates to 
distinguish recombinants from SacB mutants (the latter would grow on kanamycin; the former 
would not), and incubated O/N at 37 ºC. Next day, colonies that grew in the Cm plates but not 
in Kan were mini-prepped. The final BAC was checked by restriction enzyme digestion and 
Pulsed Field gel analysis.  
2.1.13 Caesium chloride (CsCl) density gradient centrifugation-based maxiprep: For 
transfection of 293-SL cells with the EBV BAC, it is essential to ensure that the DNA is in its 
supercoiled form: Damaged DNA has a higher change of integrating into the host cell genome 
and consequently not allowing the production of viral particles. For this reason, caesium 
chloride density gradient centrifugation was used for the isolation and purification of 
supercoiled DNA. A colony from a fresh plate was picked into 1 ml of SB with Cm and 
incubated during the day in a 37 ºC shaking incubator; the culture was transferred to a 2 l 
conical flask with 500 ml SB with Cm and incubated ON at 37 ºC, shaking. The next day, 
cells were poured into appropriate angle neck bottles and spun at 4000 rpm in a Sorvall SLA- 
3000 rotor for 15 min. The supernatant was discarded and the pellet was resuspended in 40 ml 
of GTE, and cells were lysed with 80 ml of P2, added whilst swirling and then inverted 10 
times; 60 ml of cold P3 were added to neutralise and then inverted 10 times and immediately 
incubated on ice for 15 min before being spun at 6000 rpm for 30 min at 4 ºC; the supernatant 
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Figure 2.4: Two boxes A and B showing different stages in the recombineering process, each one of the boxes 
shows what is happening in the competent bugs (left hand side) vs what is happening at a genomic level (right);  
A. The first box shows the co-transformation of the competent bacteria carrying the HB9-W4 BAC, with the 
kanamycin vector carrying the mutated W repeats (in green flanked by red homology regions) and the recA 
producing plasmid (in green); right hand side shows in detail the homologous recombination process: the 
homologous regions – either C or Y exons – of the pKovKan plasmid (red boxes) and of the HB9-W4 BAC(blue 
boxes) are recognized by recA, that promotes the recombination, giving rise to a co-integrant that possesses all 
the pKovKan plasmid incorporated into the EBV-BAC; both the Cm and the Kan resistance genes are present in 
the co-integrant; the sacB gene, that confers sensitivity to sucrose is also present in the co-integrant; B. The 
second box shows the resolution of the co-integrant by a second transformation of the resulting competent bugs 
that carries the co-integrant with the recA producing plasmid, where the goal is to remove the pKovKan 
backbone leaving only the EBV genes in the HB9-W4. There are several possible outcomes from this process, all 
shown in the right hand side: I. The co-integrant doesn’t recombine but the sacBII gene is mutated, making it 
able to grow in the 5% sucrose media because the gene is inactive. This unwanted mutant can be identified as it 
can grow on a Cm + K plate. II. The recombination occurs in the same homologous region as generated the co-
integrant, excising all of the inserted elements from the BAC: in this case the BAC reverts to being a W 
knockout, and is able to grow in a Cm media only and in the sucrose media as well; III. The co-integrant is 
correctly resolved and the resulting recombinant BAC retains confers resistance to Cm, and sucrose sensitivity 










was filtered through a cell strainer and spun at 7000 rpm and 4 ºC for 15 min before filtering 
again. 0.6 – 0.7 volumes (90 ml approx.) of isopropanol were added to precipitate the DNA, 
and left 30 min at RT before spinning at 6500 rpm and RT for 25 min; pellet was washed 
carefully with 5 ml of 70 % EtOH and left to dry for 10 min; finally the DNA was 
resuspended in 4 ml of TE. 4.3 g of CsCl were weighed and dissolved by adding 4 g of DNA 
solution (topping up with TE if required) and gently inverting. Once dissolved, 200 µl of 
Ethidium Bromide were added and the mix was loaded in a Beckman ultracentrifuge tube (5.1 
ml Quick-seal tubes; cat 342412) using an open syringe with a 19 G blunt end needle and 
allowing the liquid to flow by gravity. The tubes were then heat-sealed while ensuring the 
absence of bubbles and loaded in a Beckman NVT65.2 rotor (screws tightened to 120 lbs/in 
with a torque wrench) and ultracentrifuged under vacuum at 45000 rpm and 20 ºC, for more 
than 12 h with maximum acceleration and minimum deceleration. The next day, tubes were 
carefully removed from the rotor and pierced in the top with a 25 G needle to release pressure 
and allow for the entry of air. Using a 19 G sharp syringe, about 1 ml of DNA was removed 
from the lower red band, taking care not to touch the RNA pellet in the bottom of the tube; the 
DNA was transferred drop-wise to a 15 ml falcon to avoid shearing of the DNA and mixed 
with fresh CsCl mix to a final volume of 5.2 ml; 70 µl of EtBr were added to the mix and 
centrifuge tubes were loaded and sealed as previously. The samples were spun under vacuum 
at 60000 rpm O/N using the same settings as before. The next day, 0.5-1 ml of DNA from the 
lower band was again extracted using a needle and cleaned of EtBr by adding TE-saturated 
butanol (top layer) up to 2 ml and inverting, spinning at 13000 rpm for 15 s and discarding the 
top pinkish layer with a pipette. Washes were repeated until the butanol layer was clear (not 
pink) and then twice more – typically six extractions. DNA was finally precipitated by adding 
0.5 vol of NH4Ac and then 2.5 vol of absolute EtOH (before adding the ethanol the sample 
had to be split in 570 µl per 2 ml tube) and spinning at 13000 rpm for 10 min. The pellet was 
washed in 200 µl 70 % EtOH, spun for 3 min and air-dried for 15 min before resuspending in 
30 µl of TE per tube. 
2.1.14 Pulsed Field Gel Electrophoresis: For diagnostic digests of fragments bigger than 10 
Kb, Pulsed Field Gel Electrophoresis was used. Gels were prepared at 1% agarose in 0.5 x 
TBE – typically 170 ml for 30 or 45 well combs. The CHEF DRII (Bio-Rad) gel tank was 
filled with 0.5 x TBE (2 l) and pre-cooled to 14 ºC. Samples were run for 12 - 14 h at 6 V/cm, 
with switch time initially 1 s and finally 10 s. The gels were then stained for >30 min in 250 
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ml of 0.5 x TBE containing 0.5 µg/ml EtBr, and then washed for 10 min in 0.5 x TBE before 
imaging using a Gel Doc XR+ (Bio-Rad). 
2.2  Cell Culture 
	
2.2.1 Cell Lines: The HEK-293-SL cell line was used for virus production. It is a subclone of 
a human embryonic kidney tissue transformed with adenovirus 5 (Russell et al. 1977), 
although they are probably cells of neuronal origin (Shaw et al. 2002). The Raji cell line 
(established from an EBV-positive Burkitt Lymphoma) was used to assess the infectivity of 
virus stocks. LCLs – Lymphoblastoid cell lines – were established by EBV infection of 
primary B cells. B cells and PBL were isolated from buffy coats of human blood donors (see 
section 2.4.1). 
2.2.2 Cell lines Maintenance: All cell lines were grown in RPMI 1640 media (Gibco), 
supplemented with 10 % FCS from GE Healthcare for the 293-SL and from Gibco for the B 
cells, and Penicillin/Streptomycin (P/S). 293-SL cells were split every 4-5 days by 1/4 to 1/6 
and they were grown with a 2 mM of L-glutamine extra-supplement in the media. 
Hygromycin (200-100 µl) was added to the media of 293-SL transfected cells to select for the 
presence of the virus. LCLs were split every 4 days, at 1:5 to 1:4 depending on cell density. 
Raji cells were split every two days, at 1:4. Media for both cell lines was supplemented with 
10 % FCS (Gibco) and P/S.  Infected PBL and B cells were grown in RPMI with L-glutamine 
containing 15 % FCS (Gibco) and P/S. For the first two weeks after infection, media was 
further supplemented with 500 ng/ ml of cyclosporine A to inhibit T cell response against 
activated B cells. 
 
2.2.3 Transfection by LID (Lipid/Integrin-targeting/DNA) vector delivery: Transfection 
of BAC DNA was based on the protocol described in Hart et al. (1998) and modified in White 
et al. (2003). Adherent cells were seeded in 1 ml in 6 well plates, and grown to approximately 
20-50 % confluence before transfection. For 1 µg of DNA, 40 µl of 0.1 mg/ml peptide 6 (I) 
were added to 0.75 µl lipofectin™ (L) and mixed by vortexing. After 5 min, 1 µg of BAC 
DNA – dissolved in a final volume of 100 µl of OptiMEM – was added to the LI mix with 
cut-off tips, gently mixed by flicking and left at RT for 20 min. After removing the media 
from the wells, 1 ml of OptiMEM was added to the LID complex and this solution was used 
to replace the media. Cells were incubated for 6 h and the transfection mix was then removed 
and replaced by HEK 293-SL growth media. Cells were left for 48 h to incubate and then 
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observed under fluorescence microscope to assess transfection efficiency. Media was then 
replaced by fresh media supplemented with 200 µg/ml of hygromycin and and left O/N. Next 
morning cells were trypsinized and each well was seeded into four 10 cm dishes in growth 
medium supplemented with 200 µg/ml hygromicin and left for 10 days with minimum 
disturbance. After that, media was replaced every 5 days until colonies were large enough to 
pick. The concentration of hygromycin in the media was then dropped to 100-150 µg/ml and 
colonies were picked once they measured 2-3 mm diameter. 
 
2.2.4 Cell Colony Picking: Media was removed from the plate. The tops of 200 µl pipette 
tips were cut off to 5-8 mm high, to use as cloning rings, and autoclaved. The cloning rings 
were dipped in autoclaved vacuum grease, and placed in a way to surround a single colony 
and isolate it from the rest of the cells; 40 µl of fresh trypsin (Gibco) was placed in the 
cloning ring and use to detached the cells; neutralization was performed with media and each 
colony was transferred to a well in a 6-well plates and grown in growth medium 
supplemented with 150 µl/ml of hygromicin. After achieving confluence, they were scaled up 
to T25 flasks and 6 cm dishes and then cultured in T75 flasks. 
 
2.2.5 Cell Seeding for harvesting: LCLs were seeded at 3x105 cells/ml and harvested the 
next day. HEK 293-SL were seeded at 1/4 in a 10 cm dish and harvest when 90 % confluent 
by scraping. Cells were washed with PBS and pellets were frozen for protein and DNA 
extraction; for RNA cells were resuspended in RLT and frozen according to the RNA 
extraction kit manufactures instructions (section 2.5.1). 
2.2.6 Episome Rescue: To check for the integrity of the episomal EBV genome in 
mammalian cells, DNA was extracted using a Low Molecular Weight Extraction method, 
similar to a mini-prep, followed by transformation into bacteria by electroporation and 
digestion analysis of mini-prepped DNA on a Pulsed Field gel. This allowed us to check if the 
EBV BAC had undergone severe changes in the cells and if it was preserved as an episome 
instead of integrated in the DNA of the host cell. 
 
a) Low molecular weight extraction prep: Cells were grown in 6 cm dishes and scraped 
into 1 ml of cool PBS. They were then pelleted for 5 min at 3000 rpm, PBS removed and the 
pellet frozen at -80 ºC. After thawing, cells were resuspended in 60 µl of STET, then lysed 
with 130 µl of SDS, neutralised with 110 µl of 7.5M ammonium acetate and left for 5 min in 
ice before spinning at 13000 rpm and 4 ºC for 30 min. DNA was cleaned by extraction against 
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phenol: chloroform: 200 µl of 1:1 mix of chloroform: phenol (saturated with 10 mM Tris 
pH=8) was added to the supernatant in MaxTract High Density tubes (Qiagen). The tubes 
were shaken vigorously for 30 s and then spun at 10000 rpm for 6 min and the upper layer of 
the tube was transferred to the next tube. It was then extracted twice against chloroform to 
remove residual phenol. The cleaned aqueous phase was transferred to a fresh tube and DNA 
was precipitated with 670 µl of 100	% ethanol followed by centrifugation, and washed with 
70	% ethanol before air drying and resuspending in 50 µl of TE supplemented with 5 µg/ ml 
RNase A. 	
 
b) Transformation by electroporation: Transformation was performed in ElectroMAX 
DH10B Cells (Invitrogen), according to the manufacturer’s instructions; briefly, 20 µl of cells 
were added to each chilled microcentrifuge tube containing DNA; the mix was then carefully 
pipetted to a pre-chilled 0.1 cm electroporation cuvette, tapped to move the content to the 
bottom, and electroporated using a BioRad GenePulser II electroporator, at 1.8 kV, 200 W, 25 
µF. Immediately afterwards, 1 ml of pre-warmed S.O.C. media was added to each cuvette and 
the contents were transferred to a 1.5 ml tube. Bacterial recovery was done at 225 rpm and 37 
ºC for 1 h before plating on 14 cm diameter LB agar plates supplemented with 
chloramphenicol. 
 
2.3 Viral Particle Production and Isolation 
	 	
2.3.1 Lytic cycle induction to produce infectious viruses: 293-SL cell clones that had been 
checked for episome integrity were then induced into lytic cycle by transfection with 2 µg of 
BALF4 and 2 µg BZLF1 expression constructs and 12 µl of Gene Juice (Merck Millipore) 
transfection reagent: Cells were seeded in 10 cm plates to be about 20 % confluent after 48 h. 
12 µl of Gene Juice were added drop-wise to 500 µl optiMEM, mixed by vortexing and 
incubated for 5 min at RT. The DNA was then added, mixed by pipetting and incubated at RT 
for 15 min. Growth media was removed from the cells and 5 ml of optiMEM were added to 
each plate, then the transfection mix was added drop-wise and left for 6 h before substituting 
the media for full-growth media without hygromycin.  
 
2.3.2 Harvesting of Viruses: 5 days after the induction of lytic cycle, the supernatant 
containing viral particles was harvested. Media from the 10 cm dishes was filtered through a 
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0.45 µm filter using a 50 ml syringe to separate the viral particles from any cells in suspension 
and cell debris. Virus-containing supernatant was stored at 4 ºC until required. 
2.3.3 Counting of Raji’s infective units: Raji cells were seeded in a T75 flask from a 1:4 
split at around 2x105 cells/ml. Next day a 10 fold serial dilution of the virus was made using 
111 µl of the harvested supernatant from the infected cells and adding it to 1 ml of growth 
medium in a 24 well plate. After adding the virus to the first well 111 µl  was taken from the 
first well and added to the second and so on, and then discarded from the last well. This left 
the first well containing 100 µl of virus, and the subsequent wells having serial 10-fold 
dilutions of this.  Raji cells were counted, and resuspended at 2x105 cells/ml. 500 µl of Raji 
cells were added to each well and the infection was incubated for 2 days, after which 0.5 ml 
of media containing 20 nM  TPA and 5 mM Sodium Butyrate was added to each well and left 
overnight. The next day, cells were pipetted up and down to break the clumps and left to settle 
in the incubator for 15 min, before counting under the fluorescence microscope. A control 
virus of known titre was also used to compare the number of green cells. 
2.3.4 BALF5 gene quantitation: qPCR of BALF5 is a method to quantify the total quantity 
of viral DNA. The PCR reaction for BALF5 was set up using a final volume of 10 µl in the 
following way: 5.0 µl of Takyon Low Rox Probe MaterMix dTTP Blue master mix 
(Eurogentec), 0.2 µl of reverse primer, 0.2 µl of forward primer (20 x, stock concentration of 
300 nM), 0.2 µl of BALF5 probe FAM label (stock concentration of 250 nM) and 0.4 µl mQ 
water; 6.0 µl of the mastermix was distributed to each well  and 4 µl of DNA or standard 
(amounts per reaction). To use as standards, dilutions were prepared from DNA extracted 
from Nawalma BL cells and adjusted to a concentration of 132 ng/µl. Each one of these cells 
contains 2 integrated EBV genomes and 6.6 pg of total DNA. The DNA corresponds to 40 
000 EBV copies/µl. A serial dilution was made from the original concentration to contain 
4000, 1000, 200, 40, 8 and 1.6 EBV genomes/µl to use as a standard curve. A pre-DNase step 
was done in some cases to remove all traces of contaminant cell DNA from the supernatant. 
After this step 15 µl of viral supernatant were added to 15 µl of lysis mix and incubated for 1 
h at 55 ºC and then for 99 ºC for 10 min. Lysis mix was prepared by adding 50 µl TWEEN 20 
to 50 µl of proteinase K (20 mg/ml stock), making up the volume to 5 ml with ddH2O. 
 
2.3.5 DNAse treatment of viral supernatant: A pre-DNase step was done in some cases to  
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remove all traces of contaminant cell DNA from the supernatant. For this, 10 x DNase 
reaction buffer was added directly to the RNA along with 1 µl	of Precision DNase (Primer 
Design), to each 100 µl of RNA; reaction was done at 30 ºC for 15 min and inactivated at 55 
ºC for 5 min. 
 
2.3.6 Concentration of Viral Particles: Because of the low titres obtained, some of the 
viruses had to be concentrated by ultracentrifugation. Supernatant extracted from several 10 
cm dishes previously induced for lytic cycle were harvested as described previously and 
bacitracin was added to a final concentration of 10 µg/ml. Bacitracin has been shown to 
improve the recovery of virus particles (Nemerow & Cooper 1981). Samples were then 
centrifuged in 30 ml conical (Beckman ref 358126) open tubes in a SW32.1 rotor, at 19200 
rpm for 2 h at 4 ºC, max acceleration and max deceleration. Pellets were resuspended in 1 ml 
PBS.  
2.4 Infection of Primary B cells and Early Infection Study 
	
2.4.1 PBL Extraction from Blood: Blood bags containing residual cells left after the buffy 
coat extraction of platelets – buffy coat residue (UK National Blood and Transplant service) - 
were sprayed with EtOH and the content of the bag was poured into a T75 flask. Using cold 
PBS, the volume was topped up to 200 ml and mixed; 25 ml of blood were slowly layered 
onto 25 ml Ficoll-Paque Plus (GE Healthcare) in each of eight 50 ml centrifuge tubes 
(Falcon) avoiding disruption of the interface. Tubes were spun at 1380 rpm for 30 mins at 18 
°C with brake OFF (acceleration 1/break 1). Lymphocytes were then extracted from the grey-
white interface layer that separates the ficoll from serum using a 5 ml pipette; the cells were 
pooled in 250 ml bullet tubes containing 100 ml of pre-chilled wash buffer [RPMI + 2% FCS] 
and spun at 1380 rpm, 5 min Brake off, 9 acceleration and 4 ºC. The supernatant was removed 
into a waste container and 200 ml of wash buffer were added and used to resuspend the pellet 
and repeat the wash step. The pellet was resuspended in 50 ml of LCL outgrowth medium (15 
% FCS) and filtered through a 70 µm cell strainer. Cells were kept on ice and a 1:10 dilution 
was used to count them. PBL fractions of cells were retained at 2x106 per ml in 5 ml for FACs 
analysis. 
2.4.2 B cell Isolation from total PBS: To isolate B cells, 109 PBL cells were spun at 1100 
rpm for 5 min in a 50 ml conical centrifuge tube and resuspended in 8 ml MACS running 
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buffer (PBS-EDTA-0.5% BSA) [80 µl per 107 cells]. 500 µl of CD19 microbeads (Miltenyi) 
were added to 109 cells, mixed and incubated in the fridge for 15 minutes. 10 ml of MACS 
running buffer were retained before installing the buffer in the AutoMACS separator; Cells 
were centrifuged and supernatant completely removed, then resuspended in 5 ml of MACS 
running buffer for 109 cells; collecting tubes (15 ml falcons) were placed under neg and pos1 
ports and cells into input port. The “Possel” (Positive selection) program was run in the 
AutoMACS separator and the isolated B cell fraction was diluted in 10ml growth media, 
counted and then seeded at 2x106 per ml. 
2.4.3 Infection of PBL to access LCL outgrowth: The assay was prepared in a 24 well-
plate, 
using 1 ml of each virus diluted to the same MOI in B cell media and 1 ml of PBL at 2x106 
cells/ml. Half of the media was replaced every week after the second week post- infection. 
2.4.4 B cell infection: Due to the difference in RGU titres it was impossible to normalize the 
concentration to the same final volume to fit the infection into a well of a 48 well plate, 
infections were therefore performed for two hours at 37 ºC in falcon tubes with the same 
number of cells and same viral MOI; after this, cells were spun and resuspended in the desired 
volume of full-growth media and plated. 
2.4.5 Harvesting of infected B cells for RNA extraction: 2x106 cells of CD19-purified B 
cells were infected at an MOI of 0.5 as described previously (section 2.4.4); each infection 
was resuspended in 1ml and 500 µl	were	plated in two wells of a 48 well-plate (106 cells in 
each). On day 3 post-infection, one of the wells was harvested; for the subsequent time points 
on the day before harvesting 0.5 ml of media were added to the cells and they were pipetted to 
break any clumps; on the harvesting day, 0.5 ml of the culture was harvested, leaving the rest 
for subsequent time points. 
2.4.6 B cell staining for cell trace FACS analysis: All of the staining steps were performed 
in the dark and cells were spun always at 3000 rpm for 5 min, CellTrace Violet (Thermo 
Fischer Scientific) was prepared according to the manufactor’s instructions, giving a stock 
solution of 5 mM  and then diluted at 1/10 in DMSO to give a final stock concentration of 0.5 
mM (1/10 of that recommended by the manufacters, due to previous evidence of toxicity for 
B cells; Agnieszka Szymula, dissertation 2016). Cells were stained with 1 µl of the diluted 
dye per ml of cells in PBS (working concentration of 0.5 µM) at 5x105 cells/ml and incubated 
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for 20 min at 37 ºC; controls of unstained B cells and PBLs were kept for calibration of the 
FACS machine. On the day of harvesting, cells were pipetted to disrupt clumps and the 
desired number of cells was harvested and volume replaced with fresh media and made up to 
1.5 ml with a 1 x PBS/ BSA cold buffer and spun for 5 min at 3000 rpm in a cold centrifuge 
to wash. Cells were resuspended in 50 µl of wash buffer with 6.2 µg of human IgG (Sigma, 
14506 made up in 150 mM NaCl) to occupy the Fc receptors and prevent non-specific 
binding, and incubated at RT for 15 min; cells were washed with 1 ml of 1 x PBS/ BSA, spun 
again and after removing the supernatant, resuspended in 100 µl of 1 x PBS/ BSA with 1µl of 
CD20-RPE antibody (Dako, R7013, clone B-Ly)  and incubated at 4 ºC for 20 min in the 
dark; cells were washed twice with 1 ml of 1 x PBS/ BSA and then resuspended in 500 µl of 1 
x PBS/ BSA supplemented with 4 µl DRAQ7 (Biostatus, DR71000)  as a live/dead cell stain 
and analysed immediately by FACS. 
2.5 RNA Extraction and Analysis 
	
2.5.1 Total RNA extraction from mammalian cells: Cell pellets were resuspended in 350 µl 
of RLT buffer (Qiagen RNeasy Mini Kit) supplemented with 10 µl of beta-
mercaptoethanol/ml by vortexing, prior to freezing at -80 ºC. After thawing, the lysate was 
homogeneized by passing 8 times through a 25 G blunt needle attached to a 1 ml syringe; 
RNA was extracted from the lysate using the RNeasy Mini Kit (Qiagen). 
2.5.2 DNase treatment of RNA samples: RNA samples were incubated 10 min at 30 ºC with 
the DNase enzyme from the DNase Precision Kit (Primer Design); the enzyme was then 
inactivated at 55 ºC for 5 min. 
2.5.3 cDNA synthesis from total RNA: cDNA was synthesised using the Transcriptor First 
Strand cDNA Synthesis Kit (Roche, cat 04379012001) using random hexamer primers. After 
mixing of the primer with the template RNA, an optional incubation 65 ºC for 10 min was 
done, to allow increased denaturation of RNA secondary structures. The reaction was 
performed at 25 ºC for 10 min and 55 ºC for 30 min and then inactivated at 85 ºC for 5 min. 
Samples were kept at 4 ºC for short term use and frozen at -20 ºC for long term storage.  
2.5.4 Real-Time quantitative PCR: Real-Time PCR was performed on a QuantStudio 7 
Real-Time PCR System with a 384-well block (Applied Biosystem) using either SYBR Low 
ROX kit (Kapa Biosystems) or Takyon Probe Low Rox kit (Eurogentec). The cycling 
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conditions were 95 °C for 3 min, followed by 40 cycles of 95 °C for 10 s and 60 °C (for 30 s 
for SYBR or 60 s for Takyon). Dissociation curve analysis was performed for SYBR green 
assays at the end of each run to check for the absence of non-specific products. Quantification 
of mRNA levels was carried out using the Delta-Delta Ct method. Results were analysed 
using DataAssist Software v3.01 (Thermo Fisher Scientific). mRNA levels for each target 
gene were normalized to 2 housekeeping genes: ALAS1 and RPLP0. WT-infected cells 
harvested on day 4 were used as a reference. 
2.6 Protein Extraction and Analysis 
	
2.6.1 Protein extraction from mammalian cells by RIPA: Seeding and harvesting of cells 
for protein extraction was done as described in section 2.5. Protein extraction was induced by 
resuspending the cell pellet in 70 µl of Protein Lysis Solution and causing mechanical distress 
in the cells (pipetting up and down several times); a 5 min incubation on ice was done before 
spinning at 14000 rpm and 4 ºC for 10 min. Supernatant was transferred to a fresh tube and 
protein concentration was determined. 
2.6.2 Protein Quantification: Proteins were quantified using the Biorad DC Assay (based in 
the Bradford method); briefly, a standard curve was plotted using standards of bovine plasma 
gamma globulin prepared from a 1.35 mg/ml stock. The standard concentrations used were 0, 
0.2, 0.5, 0.75, 1.0 and 1.35 mg/ml in 20 µl of RIPA solution. 1 µl of sample was diluted in 19 
µl of RIPA lysis solution; 100 µl of working solution A (which is 20 µl of Reagent S per ml 
of reagent A) was added to the samples and vortexed. Then 800 µl of reagent B were added 
and samples were vortexed again. After 15 min at RT, all samples were transferred to plastic 
cuvettes and quantified by interpolation from the standard curve measuring the absorbance at 
750 nm. 
2.6.3 SDS-PAGE electrophoresis: Protein separation by size was performed using sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). The 0.75 mm gels 
consisted of a resolving gel (7.5 % acrylamide, or 12 % for EBNA-LP gels) and a stacking 
gel. Gel polymerisation was induced by using 10 % APS (stock concentration) and TEMED. 
Prior to loading, protein samples were mixed 1:1 with 2 x SDS sample buffer and loaded in 
equal amounts (typically 20-30 µg of protein per lane). The mini-gel was run in a BioRad 
Protean II system at 150 V for 75 min in SDS running buffer.  
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2.6.4 Transfer of proteins from a gel to a membrane:	Proteins separated by SDS-PAGE 
electrophoresis, were transferred into a nitrocellulose membrane by an electroblotting at 100 
V for 1 h in a transfer buffer cooled by an ice pack, using a Bio-Rad mini-Protein system.  
2.6.5 Western blotting:	The nitrocellulose membrane blotted with protein was blocked in 5 
% milk in PBSt for 1 h on a shaker at RT. The blocking solution was then replaced by the 
primary antibody prepared in 10 ml of blocking solution and incubated O/N at 4 °C, shaking. 
The following day, the membrane was washed 3 times, shaking for 10 min with PBSt. The 
secondary antibody conjugated to HRP was diluted at 1:2000 in blocking solution was added 
to the membrane and incubated for 1 h at RT, shaking. The membrane was washed 3 x 10 min 
with PBSt. To visualize proteins, the membrane was incubated for 5 min with 2 ml of a 1:1 
mixture of ECL solutions A and B (ThermoFisher), wrapped in Saran wrap and exposed to 















Chapter 3: Results  
	
3.1 Generation of six W repeat constructs and quality control 
 
As mentioned in section 2.1.10, introducing modifications to the EBV genome in the 
BamW repeat region is achieved by cloning the mutation in each one of the repeats and then 
assembling them together in two steps. Only after the mutated array of W repeats is 
assembled the recombineering to introduce them in a WKO BAC takes place. 
For the assembling of mutated W repeats into an array, it is essential to include in every 
cloning step digests to control for the integrity of the BamHI restriction sites, as well as the 
flanking regions of the W exons. Because of the complex and multi-step cloning process, the 
likelihood of the occurrence of spontaneous mutations must be taken into account; small 
changes in a single repeat are not very likely to have phenotypic consequences in the virus or 
complicate the cloning process, so the constructs are not generally sequenced. The enzymes 
chose for the control digests allow to detect major changes (>100 bp) resulting from insertions 
or deletions. The series of plasmids generated to make recombinant viruses in this study is 
described in figure 3.1, and the digests used for the quality control in each step are described 
in table 3.1.  
After the generation of the five single mutant repeats, the three repeat unit constructs were 
assembled together. During the second GA of the sisRNA-2 triple mutants and the sisRNA-1 
point mutants, it was verified that the 3+3 W repeats GA step was not successful. 
Table 3.1: Diagnostic digests used in each step of the cloning process 
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Figure 3.1: Representation of the cloning process followed to obtain a recombinant EBV BAC, containing the 
desired mutations in each one of the 6W repeats. All of the plasmids named pAGxxx were generated by me 
during the Project; the plasmids represented in orange boxes are the ones used to create the BsmBI point 
mutants (sis1PM), the green boxes contain sis1KO mutants and the blue boxes represent the sisRNA-2 triple 
mutants (sis2TM); each column corresponds to a different step of the cloning process; the pKovKan vector 
cloning presents two alternative vector plasmids, pMR010.1 and p4467.1, that generate equivalent products 
designated respectively by a and b. The number after the dot represents the mini-prep ID of the plasmid 
used.The boxes with a red outter line were plasmids produced with errors.  
Although constructs containing both the C and Y ends of the repeat array were 
generated, digestion of the cloning product with the HindIII restriction enzyme, that cuts the 6 
repeat construct on both edges of the ampicillin vector, shows that the constructs are about 6 
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Kb shorter than predicted. The plasmid carrying sisRNA-1 deletions was the right size (figure 
3.2A), which is slightly shorter than the control plasmid because of the deletion of the ~80 bp 
sisRNA-1 region in each one of the repeats. Analytic digests in the sisRNA-1 point mutant 
(sis1PM) and sisRNA-2 triple mutant (sis2TM) deficient plasmids were performed in both the 
ampicillin vector and the pKovKan vector, showing that the kovkan backbone was also as 
expected; the two 2.3-3.6 Kb bands obtained in all of the KovKan constructs show the core 
repetitive structure of the vector plasmid is intact, once the cutting sites are contained in that 
region. (figure 3.2A) and the cloning problem occurred within the repeat array. The KovKan 
digest of sis2PM was similar to sis1PM and it is not shown. 
Figure 3.2B shows that digestion of the Y side of sis1PM and the sis2TM with BamHI 
and MluI lacks the 3072 Kb band present in the control (that contains 3 fragmets of the same 
size), indicating a point mutation in two of the BamHI restriction sites, that might be the 
reason behind the problems when assembling the two sides. 
Based on the several restriction digests, it was verified that the most likely event to 
cause the shortening of the 6 repeat constructs was the loss of two internal repeats, in the 3W 
repeat construct containing the Y unique region extremity (figure 3.2B). Looking at figure 
3.2C, it is easy to understand that the plasmid derived from p8376.3 contains both of the 
mutated regions. One can speculate that the identical nature of the repeats somehow caused 
kinetic instability in the cloning process that allowed one of the repeats to be ejected from the 
construct. This explanation does not necessarily account for the fact that the same parental 
plasmid, also used to construct the C side (see section 2.1.10 and figure 3.1) didn’t cause 
problems in that construct nor in the sis1KO mutants.  
Although the assembly of the 3W repeats construct – Y side was repeated several 
times with a newly cloned p8376.3 derivative for the defective mutants, the problem was 
recurrent, so the cloning of the BsmBI and triple sisRNA-2 mutants was abandoned, and only 
the sisRNA-1 KO mutants proceeded to the generation of the EBV BAC and viral production.  
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 Figure 3.2:	 A -Diagnostic digestion of the 6W repeats constructs (in both the Amp pBR322 and  KovKan 
backbone) showing that the sis1PM and the sis2TM are shorter by 4-6 Kb than predicted, indicating that there 
was a missing part of the BamHI repeats;; B- While the 3W repeat C side of the constructs are similar to the 
control when digested with EcoRI/BamHI , the MluI/ BamHI digestion of the Y side of sis1PM and the sis2TM 
lacks the 3072 Kb band present in the control; C- Squematic representation of the 3W repeat constructs, 
including the position of the restriction sites refered in B and the lenght of the fragments obtained after 
digestion, the light blue region indicates the fragment of 10 kB in the Y side and the dark blue indicates the 
parental plasmid that comprises the two defective BamHI sites. 
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3.2 Generation of recombinant BACs 
	
The sis1KO constructs were chosen to generate recombinant BACs; two independent 
mutants, pAG027 and pAG028 made from different mini-preps at the 3W repeat level (see 
figure 3.1).  
For the BAC generation, as previously explained (see section 2.1.10 and figure 2.4), 
the first step is to select for the recombination constructs to combine the KovKan vector 
plasmid with the BAC genome; the second step is to eliminate the vector plasmid from the 
BAC, hoping to leave behind the modification. The co-integrants were checked by restriction 
digest with enzymes that are multiple cutters in the BAC, cutting once in each repeat several 
times in the remaining parts of the construct, and compared against the W4 BAC, previously 
described (see section 1.9) and against the wild-type HB9 BAC. Figure 3.3 and 3.4 show 
examples of restriction profiles of two enzymes.  
Recombination can occur in the C extremity, or in the Y extremity, giving rise to 
either C or Y recombinants. Because one of the two sites might confer more kinetic stability 
than the other for the future solving step, both types of co-integrants C, Y were used to make 
competent bugs.  
 
Figure 3.3: Age I digest of co-integrants; in red the ones that were chosen to make competent bugs. 
For the pHB-W4-pAG027 and -pAG028 BACs the co-integrants chosen were 
pAG027+1, pAG027+4, pAG028+11, pAG028+12 as shown in figures 3.3 and 3.4. We can 
see that pAG027+1 and pAG028+12 have a restriction profile for AgeI that has a higher band 
Age I
1    2    3    4    5    6     7    8    9    10   11   12 1    2    3     4    5     6    7     8    9   10  11  12
pHB-W4-pAG027+ pHB-W4-pAG028+
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at around 17 Kb followed by a duplet of a 15.5 Kb and a 14.7 Kb bands while the pAG027+4, 
pAG028+11 co-integrants have a higher band at 22 Kb and don’t have the duplet. They are 
distinguishable from W4, the WKO that presents a 15.5 Kb and 14.7 Kb duplet but not the 17 
Kb band. The EcoRI profile shows a band at 42 Kb followed by a 30 Kb band for pAG027+1 
and pAG028+12 while for pAG027+4, pAG028+11 co-integrants the higher band is the 30 
Kb and followed by 27 Kb. Unfortunately the W4 BAC loaded was to diluted to see clear 
bands, so as a control, the profile from previous digests was analysed. 
 
 
Figure 3.4: Eco RI digest of co-integrants. Red circles indicate the clones that were chosen to make competent 
bugs for resolution to the final recombinant. 
During the second transfection with pDF25tet, a second recombination takes place in 
the Y or C sites; for the Y co-integrants, recombination occurs in the C site, and vice-versa. 
Digest with EcoRI shows the mini-prep of several colonies from each of the solved co-
integrants. The final recombinants chosen for transfection of HEK293-SL cell lines were 
HB9-W4-pAG027+1.12, -pAG027+4.6, -pAG028+11.11 and -pAG028+12.6 (figure 3.5). We 
can see that the correct resolved BACs two bands at around 25 and 23 Kb; the mini-preps like 
-pAG27+1.9 that have a higher band at 48 Kb and only present the highest band of the 
referred duplet are revertants, that lost the repeat region because they recombined both times 
in the same recombination site (+C.C or +Y.Y recombinants); the ones like -pAG27+1.8 are 
SacBII mutants, that were not successfully eliminated in the sucrose negative selection. 
Again, the HB9 and W4 controls could not be used because the digestion did not work for 
them and comparison was made with previous digests. 
Eco RI





Figure 3.5: EcoRI digest of resolved BACs. Red circles indicate the clones that were chosen to further 
purification of DNA. 
	
3.3 Maxi-prep: Isolation of supercoiled DNA for Transfection 
 
As previously mentioned, when EBV infects B cells, the viral DNA is kept as an 
episome, by EBNA-1. However, it has been observed that when HEK293-SL are transfected 
with nicked viral DNA, it often results in the integration of the viral DNA into the host 
genome,  (reviewed in Morissette & Flamand 2010). This process might affect the normal 
translation of the viral genes, and for EBV prevents the production of infectious virus, so to 
mimic the physiological conditions of the infection it is important to ensure that the DNA use 
for transfection is in the supercoiled form. For this purpose, a maxi-prep using CsCl gradients 
and ultracentrifugation is used to separate the supercoiled from the linear and nicked DNA. 
Supercoiled DNA can be identified as  for DNA plasmids up to 20 Kb, the supercoiled DNA 
runs faster than the nicked forms in a PF gel, while for bigger fragments this order is inverted, 
making the supercoiled DNA the highest form in the gel (Cole & Tellez 2002). 
The supercoiled DNA isolated from the lower band in the CsCl gradient, and cleaned 
of ethidium bromide, was checked by digestion with restriction enzymes that are multiple-
cutters, as well as run undigested. A positive control for the EBV-HB9 plasmid was used to 
compare the band heights, as shown in figure 3.6. The BACs maxi-prepped by this method 

























construct, kindly provided by Agnieszka Szymula, to use as a reference not only for the maxi-
prep itself but also for the subsequent transfection into HEK-293-SL cell lines.  
 The bigger fragment in the HindIII and EcoRI digests of the pAG027+1.12 maxiprep 
is slightly higher than in the other independent constructs. For that reason, pAG028+11.11 





Figure 3.6: Analytical digest performed on the maxi-prepped BACs and run in a Pulse Field Gel. The undigested 
run of the isolated supercoiled DNA shows that there is little to no contamination with residual fragmented 
DNA, however, it is possible to see a low intensity band below the supercoiled DNA that corresponds to the 
nicked topoisomers, impossible to eliminate completely. 
	
3.4 Episome integrity test in the producer cell lines 
 
 
After transfection with the mutated BACs, HEK 293-SL cell lines were selected with 
hygromycin B (since the BAC carries a hygromycin resistance gene; see section 2.2.2) and 
colonies of resistant cells that also expressed GFP were isolated and expanded. Episome 
integrity was tested, before proceeding to test viral induction. From the two independent 
sis1KO generated and maxipreped - pAG027 and pAG028 derivatives - only pAG028+11.11 
was successfully transfected, as seen by the GFP expression in the cell lines. The others didn’t 
produce any clones. The transfected cells gave rise to 7 colonies that could be established into 
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To check for the integrity of the episome in the cell line, to make sure there were not 
missing regions, low molecular DNA extraction technique was used to isolate non-
chromosomal DNA. The extracted DNA was transformed into electro-competent bacteria by 
electroporation (see section 2.2.6); using this method only circular plasmids are able to 
replicate in the bacteria and give rise to a resistant bacterial colony; the mini-prep of the 
colonies could then be used to assess the integrity of the genetic material. No bacterial 
colonies were establish from the genetic material from clones C2 and C3, while clone C4 
didn’t grow enough in cell culture for DNA harvesting. Clones C6 and C7 didn’t survive the 
expansion process. Clones C1 and C5 were chosen to produce viral particles because the 
constructs are almost the same as the parental BAC used to transfect the cell line (figure 3.7). 
The only difference is that both of them present a slightly higher and fuzzy band at around 12 
Kb, for some of the mini-preps. This band contains the TR and the BALF0 0RF, so probably 
there is a small difference in the size of the TR. 
  
 
Figure 3.7: Episomes from clones C5 and C1 rescued from HEK 293-SL cells stably transfected with the sis1KO 
pAG28+11.11 BAC. The parental BAC was used as a control as indicated. 
	
3.5 Pre-existing Cell Lines 
	
HEK 293-SL producer cell lines and LCLs containing several EBV recombinants with 
different sisRNA mutations and their control were recovered from liquid nitrogen and used to 
perform comparative analysis of protein expression and mRNA. The mutations in these EBV 
genomes are detailed in figure 3.8. The ID of each of the mutants recovered is presented in 
Clone 1 Clone 5





















table 3.2, as well as the source of the B cells used for infection and LCL production. LCLs 
were produced in two sets: one set was produced with B cells from 2 mixed donors 41/42 (the 
same donors for all of the mutants in that cluster) isolated from buffy coat residue, and the 
second group was produced with B cells isolated from leucocones from donor A4 and initially 
grown on feeder cells.  
 
 
Figure 3.8: Squeme representing the mutations in the cells lines.  
 The 293-SL producer cells displayed very different recovery speeds; both the LPrevi s 
and LPKOi 2.6 took a longer time to attach to the flask than the remaining cell lines, and they 
needed splitting less often. This observation corresponds to A. Szymula work where she 
reported that those cell lines had problems attaching to the flask, even requiring collagen- 
coated flasks to be cultured (personal communication).  
Table 3.2: Source of the cells unfroze for experiments; The LCLs signaled with the letter a are from buffy coats 
while letter b represents the LCLs from leucocones and grown with feeder cells 
 WT LPKOi LPrevi WTw LPKO 




WTw 85+1.17B2 LPKO 
86+2.26 C3 
LCL   b. WT HB9 D3 
No LCL 
a. LPrevi 2.6 
b. LPrevi 2.6 
b. LPrevi 1.28 

















3.6 Infectivity test – Raji Cell Infections 
 
The production of infectious particles by the EBV 293-SL transfected cell lines, was 
stimulated by transfection with plasmids carrying the BZLF-1 and BALF-4 lytic genes (see 
section 2.3.1). The number of infectious particles produced by each cell line was quantified 
by infection of Raji cells. Since the viral genome carries the GFP gene, we counted the 
number of GFP-expressing cells under a fluorescence microscope, to estimate the viral titre. 
One of the disadvantages of this method is the fact that, when low titres are obtained, it is 
impossible to know if the cell line is in fact producing fewer particles or if there is reduced 
infectivity of the mutant viruses.  
The first two clones obtained for the sis1KO mutant (C1 and C2) were titrated at the same 
time as an EBNA-3Arev virus stock (previously produced by the White group) that has a 
known titre (approximately 250 GRU/µl). Re-titrating this control allows to the detection of 
any problems with the Raji infection. The titres obtained from the sis1KO 293 cell lines were 
reproducibly low, while EBNA-3Arev gave reliably higher titres. This could be either a 
biological consequence of the lack of the sisRNA-1 or it is possible that the low number of 
GRU is reflecting a low infectivity ability of the viral particles, instead of a low number of 
particles. To see if this was the case, the load of viral genomes in the supernatant was also 
determined by qPCR for the BALF5 gene (see section 2.3.4). This was undertaken both with 
and without a DNase treatment to degrade viral DNA that was outside the virus particles. The 
very significant difference between the viral DNA loads found in the groups with and without 
the DNase treatment, as seen in table 3.3 confirms that the treatment with DNase is an 
important step to increase the accuracy of the qPCR. The BALF5 qPCR data (table 3.3), 
shows that viral loads for the sis1KO mutants were much lower than for the EBNA-3Arev, 
which is consistent with the infectious titres. The number of genomes comparing with the Raji 
infection titres were very variable so it is hard to say whether there is a smaller proportion of 
viable viruses, or there is experimental variability. Because the titres were insufficient for 
further experiments, transfections of HEK293-SL cell lines with the mutant BAC was 
repeated in order to generate new clones. 
Clone 5 was later found to produce the highest titres for the sis1KO mutants (typically 9.6 
GRU/µl), but it was still low compared to other viruses; for this reason, the clone 5 producer 
cells were expanded and induced into the lytic cycle in multiple 10 cm dishes, to obtain high 
volumes of supernatant that were then concentrated by ultracentrifugation: from 15 10 cm 
dishes, each with 12 ml of media, the total volume of 180 ml at 6 GRU/µl  was obtained. 
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After concentration, a final volume of 2.5 ml contained 420 GRU/µl, which corresponds to a 
97 % recovery of the viruses. 
Table 3.3: Virus titres determined by Raji infections and qPCR on BALF5 with and without a DNase treatment 
prior the viral DNA extraction; also shown are the calculated % of decrease with DNase treatment and the 
calculated number of genomes per GRU for each sample. 
 
3.7 PBL Infection 
 
In order to assess if the sis1KO mutants were able to infect B cells and generate LCLs, 
PBLs from buffy coat residues of two donors were isolated and mixed together, in order to 
minimize donor dependent variability, and infected with mutant and control viruses. EBNA-2 
rev was used as a WT control virus and cells were infected at an MOI of 2. 
Pictures of the cells were taken during the infection, to record any phenotypical 
differences between cells infected with the different mutant viruses (figure 3.9). The pictures 
shown that by day 9 post-infection EBNA-2rev infected cells exhibit a much higher density of 
cell clumps than sis1KO. By day 16, although it is not very obvious in the pictures, 
observation of the cells under the microscope clearly showed a difference between the sis1 
KO infected cells, that had small and medium size clumps, dispersed within the dish, and 
EBNA-2 rev that had more and larger clumps; the colour of the media was also different, the 
first was much more pinkish while the second had become yellowish because of the change in 
pH caused by the production of metabolic products from the expanding cells.  
The clumps of both continued increasing in size and density and by day 25 post-infection 
the clumps formed by the two viruses were almost similar in size and density; by day 30 both 
groups of infected cells displayed big clumps of B cells, shown by LCLs. Curiously, the cells 
infec 












5.17 x102 undetectable 2.39x103 
Decrease % with DNase treatment 58 undefined 28 
Genomes/GRU 150 0 15 
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ted with both viruses were clumping mostly on top of dendritic cell layers. The uninfected 
control cells did not proliferate at all, as expected. The clumps produced by both viruses 
continued to expand after the 30 days, forming LCLs. This experiment allowed to conclude 
that sisRNA-1 is not essential for LCL establishment, but suggests that sis1KO EBV induces 














Figure 3.9: 10x magnification Microscopy photos taken during a 30 days period after PBL infection with sis1KO 
C5 viruses and EBNA-2rev viruses. 
	
3.8 Primary B cell Infection 
 
To to more accurately assess the relative transformation efficiencies of the mutant and 
wild-type viruses, other infection time-courses of isolated B cells were performed following 
this experiment. Halder et al. (2009) showed that although EBV also infects T cells at low 
efficiency, CD19, a specific surface antigen marker for B cells was detected in greater than 
90% of the infected cells, among the mixed population of PBMCs. 
Infection of CD19-purified B cells from two independent buffy coat donors were performed 
in parallel using WTw 1.1 and LPrevi 2.6 viruses as well as the sis1KO C5 (figure 3.10). By 
day 7, a difference in clump size between sis KO and WTw 1.1 was seen in donor 43 but it is 
not so clear for donor 44; on days 14 and 21, cells from both donors present an obvious 
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clump density and size was the same. Both viruses in both donor cells were able to form 
clumps with the shape characteristic of LCLs within a 30 days window. 
The behaviour of sis1KO matches previous observations of the transformation 
efficiency of LPrevi. However, in my experiment, LPrevi 2.6 virus behaved in a different way 
from previous observation (Symula, dissertation 2016): despite this virus being reported to be 























Figure 3.10:  Microscopy pictures of an infection of B cells isolated from buffy coat residues of two independent 
healthy adult blood donors (donors 43 and 44, indicated); the x axis represents the different time-points and the 
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day 7, after which cells infected with LPrevi 2.6 seemed to die, behaving similarly to 
uninfected B cells (or LPKOi). 
 
Figure 3.11: Photos from microscopy, taken with a 10x magnification objective of isolated B cells during a time 
course that lasted 30 days post-infection; the x axis represents the number of days post-infection while the y axis 
shows the different mutant viruses used to infect the cells; 2x 106 B cells were used per infection and infected at 
MOI 0.5 with 1x106 viruses.  
 
A bigger scale B cell infection of cells from two mixed donors was performed in order 
to run proliferation analysis and to produce a time course to study RNA expression. The 
























observation of the formation of clumps and their increase in size during the transformation 
process that culminates with LCL establishment (figure 3.11). 
By day 7 we can observe the most clear differences between sis1KO and the WT; 
while EBNA-2rev, LPrevi and WTw1.1 are forming big and dense clumps, sis1KO is just 
starting to form small clumps, simillarly to LPKO. 
Between day 7 and 13, sis1KO clumps reach the same size as EBNA-2rev and WTw, 
showing a big change while LPKOW increases but less obviosly, and LPrevi stays practically 
inaltered. From day 13 onwards, cells infected with sis1KO behave very similarly to the WT 
and EBNA-2rev, growing more compact until they establish LCLs. LPKOW also establishes 
LCLs, while slower, but LPrevi starts dying as we see the clumps become smaller and smaller, 
an observation supported by the RNA quantification from those time-points, that had similar 
levels to the uninfected control.       
3.9 Proliferation Assays 
 
As previously mentioned, (see section 1.9), it was observed that the LPrevi viruses 
made by A. Szymula induced less proliferation of infected B cells from the WT viruses, 
raising suspicions that the mutations in one of the sisRNAs could be responsible for the 
observed phenotype. To verify if there was in fact a sisRNA-1 role in the proliferation 
impairement, a Cell Trace Violet assay was used. This is a dye that is used to stain the resting 
B cell, so that after every cycle of cell division, the intensity of the stain is lower (halved) in 
the daughter cells than in the original stainned cells, allowing to observe the number of 
divisions each cell has taken. The downside of this asay is the fact that it only allows to 
follow cell replication for a limited number of replications: after around 8 cell divisions the 
dye concentration drops to levels that can no longer be detected by the FACS machine. 
Staining with Cell Trace is made in the isolated B cells previous to the infection. In this case, 
harvesting of the  infected cells for FACS analysys took place on days 4 and 8 post-infection. 
On the day of the harvesting, cells were also stainned with an Ab against the B cell receptor 
CD20 and with DRAQ7, a life/dead stain. The gating of the samples for the analyisis is shown 
in figure 3.12.  
Results for day 4 after infection were not usable, since there was a problem with the 
staining, that caused most of the cells to be lost. By day 8 after infection, a significant 
difference in proliferation is observed between the sis1KO group, with ~80 % of infected cells 
dividing more than 4 times, the WT group, with ~99 % and LPrevi, with 92 % (figure 3.13). 
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This observation of LPrevi impairment coincides with those previously made by A. 
Szymula (dissertation 2016). Furthermore, the cells infected with the LPrevi mutant present a 
different proliferation profile, with very few cells undergoing more than 3 division cycles up 
to day 8. On the other hand, LPKO, besides presenting an apparent lower proliferation by day 
8 than LPrevi, presents a different profile, with most of the cells undergoing 5 division cycles 
until day 8 similarly to the sis1KO. 
It is also curious to note that within the WT group, WTi presents a slightly lower 
proliferation than EBNA-2rev and WTw, perhaps due to the higher mutation load in the sis 
regions; however, the difference is too subtle to draw definitive conclusions. This difference 
might illustrate the low reproducibility of the assay: EBNA-2rev and WT are both expected to 
contain a single defective W repeat, and thus to behave the same way.  
Another curious difference between the WT and LPKO/ LPrevi/ sis1KO clusters is 
observed in the number of events detected by the FACS machine after gating of live, infected 
B cells. The WT EBV infections show around 60-87 % of live cells, whereas the less 
efficiently transforming virus infections contain 19-27 % of life cells (figure 3.12). If these 
mutations result in an increase challenge for the virus to enter the B cell or start expressing 
the viral proteins that allow transformation of the naive cells, the result would be a lower 
number of early infected cells or cells presenting the typical hyper proliferation profile. After 




Figure 3.12a: Gating steps of the infected B cells by day 8 post-infection; first cells were isolated by size and 
area (FSC-W vs FSC-A; SSC-W vs SSC-A) to include viable, single cell events and reject dead cells, clumps or 
duplets; than cells were gated by life vs  dead (FSC-A vs DRAQ7) to eliminate dead cells that kept the 
morphology; finally to positively select for integral B cells over cell debris that might still  be present from the 
blood, cells were separated by their size (FSC-A vs CD20),  The gating by size has to be done carefully once 
activated B cells tend to increase in size, moving to higher area and size regions in the graph; the samples are 
identified in the top of each column and under each one of the figures there is the number of events detected out 
of the total number of events.  
EBNA-2rev WTi 2.2 WTW 2.2 
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Figure 3.12b: Gating steps of the infected B cells by day 8 post-infection; first cells were isolated by size and 
area (FSC-W vs FSC-A; SSC-W vs SSC-A) to include viable, single cell events and reject dead cells, clumps or 
duplets; than cells were gated by life vs  dead (FSC-A vs DRAQ7) to eliminate dead cells that kept the 
morphology; finally to positively select for integral B cells over cell debris that might still  be present from the 
blood, cells were separated by their size (FSC-A vs CD20),  The gating by size has to be done carefully once 
activated B cells tend to increase in size, moving to higher area and size regions in the graph; the samples are 
identified in the top of each column and under each one of the figures there is the number of events detected out 
of the total number of events. 
LPKOi LPrevi 2.3 Sis1KO 
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Cell	Proliferation:	Day	8
LPKOW 2.2 EBNA-2rev WTw 1.1
WTi 2.2Sis1KOLPrevi 2.3
	
Figure 3.13: FACS analysis of B cells on day 8 post-infection, with EBV mutants; proliferation was accessed by 
stainning with Cell Trace Violet, a nuclear dye; the x-axys represents the concentration of the dye while the y 
axis represents the number of events (cells after gating) detected. 
 
3.10 RNA expression from B cell infection 
 
3.10.1 Transcription from the Cp vs Wp promoter 
After infection, EBV initially uses Wp for transcription of the EBNAs, but largely switches 
to Cp over the first few days. The level of transcripts generated from each promoter was 
assessed by RT qPCR, in order to analyse if the deletion of sisRNA-1 delays the switch from 
Wp to Cp promoters. Previous (inconclusive) analyses suggested this might be happening 
after LPKO infection.  
Because in early infection (days 4 and 8) the ratio between the number of infected cells and 
the total number of cells is low, the RNA is of low yield, and comes from a mixture of 




Figure 3.14: Use of Wp and Cp promoters in early B cell infection; RQ was calculated using the DDCt method 
where WTw day 4 was the reference sample and RPLP0 the housekeeping gene. ALAS1 was eliminated from the 
analysis because it was proven not to have a very high SD between replicates; error bars represent the SD 
between technical replicates. 
I have found the data from these early time-points has been variable and difficult to 
analyse (figure 3.12). To take into account the number of infected cells in the overall 
population, EBNA-2 was used as a normalization factor once all of the samples were first 
normalized to a housekeeping gene (RPLP0), and then expression levels are described relative 
to a reference sample (WTw Day 4) by the DDCt method. Normalization against EBNA-2 was 









































Figure 3.15: Use of Wp and Cp promoters in early B cell infection normalized against EBNA-2 expression as a 
control for the amount  of infected cells; RQ was calculated using the DDCt method where WTw day 4 was the 
reference sample and RPLP0 the housekeeping gene. ALAS1 was eliminated from the analysis because it was 
proven not to have a very high SD between replicates; error bars represent the SD between technical replicates, 
including the error of the EBNA-2.  
There is no consistent effect of LPKO or sis1 mutation on the relative use of Cp and Wp. 
There is a hint that Wp usage is slightly higher on day 4 in the sis1 mutants revi and sis1KO, 
but would need many repeats to confirm. No consistent differences are seen at other time 
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points. Also in the established LCLs, there is higher Cp activity: this experiment was better 
controlled so it might be a real effect. Because the cells are at different densities during the 
time-course, it is possible that the cell culture conditions have compromised the data; in order 
to minimize this error it would be essential to repeat the experiment several times. The LCLs 
presented in the graphics were the cell lines generated from the cells infected for this time-
course. To minimize variation between the samples, the LCLs were seeded at a fixed density 
and harvested at the same time the next day, to allow the cells to recover from these 
manipulations. LCLs’ gene expression in this experiment should be regarded more reliable 
since thay are less prone to artefacts but not quantitatively compared to the remaining time-
points. 
 By day 4, LPrevi and sis1KO have a Cp expression that is the double of the expression 
in WTw and EBNA-2rev. LPKO expression is in between this two groups. Between day 4 and 
8, LPrevi and sis1KO Cp expression continue to increase, by almost two fold, while WTw and 
EBNA-2rev don’t show any significant changes and LPKO increases but slower. It is by day 
13 that we start to see a significant increase in Cp expression of WTw and EBNA-2rev and a 
stabilization of the expression in sis1KO and LPKO. LPrevi on the other hand, starts behaving 
in a weird way which is probably related to an increase in apoptosis once by day 20 all of the 
cells infected with this virus are dead and by 13 they already present an unhealthy 
morphology (see figure 3.11) 
Wp expression should decrease as the Cp expression increases, but that is not what it 
was observed in the experiment. By day 4 the Wp expression is similar in all infected cells 
apart from LPrevi that shows a very increased expression (around 3 fold more). Sis1KO 
decrease in Wp expression can only be observed between day 8 and 13. 
Subtle increases or decreases in the expression from the promoters are impossible to 
identify because of the large SD, and lack of replicates. It seems that sis1KO starts expressing 
from the Cp promoter earlier than WT while maintaining a Wp expression stable until day 13.  
It is disappointing that the LPrevi infection did not survive long enough to act as a positive 
control for sis1KO, as if both mutations disrupt sisRNA-1 then they would be expected to 
have similar phenotypes.  
3.10.2 Expression of LMP1 
Because LPrevi previosuly showed elevated LMP1 levels at day 30 post infection 
(Szymula, dissertation 2016), LMP1 expression during the time course was analysed. LMP1 
expression shown a high increase for EBNA-2rev and WTw by day 8 and stayed constant for   
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Figure 3.16: Use of LMP1 promoter in early B cell infection; RQ was calculated using the DDCt method where 
WTw day 4 was the reference sample and RPLP0 the housekeeping gene. ALAS1 was eliminated from the 
analysis because it was proven not to have a very high SD between replicates; error bars represent the SD 

























Figure 3.17: Use of LMP1 promoter in early B cell infection normalized against EBNA-2 expression as a control 
for the amount  of infected cells; RQ was calculated using the DDCt method where WTw day 4 was the reference 
sample and RPLP0 the housekeeping gene. ALAS1 was eliminated from the analysis because it was proven not 
to have a very high SD between replicates; error bars represent the SD between technical replicates, including 
the error of the EBNA-2.  
Only by day 20 it was possible to observe a significant difference in LMP1 expression by   
sis1KO, and LPKOw. It is possible that a progressive increase takes place between day 4 and 
8, but because of the high SD of day 8 it is impossible to tell for sure. Considering the 
expression from Cp that increases after day 8, it is possible that the same pattern is followed 
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by LMP1 promoters. Unfortunately, the death of LPrevi mutant after day 13 doesn’t allow to 
draw a conclusion on the effect of the mutation at later time-points. The LMP1 levels are 
depressed early during LPKO infection. There is also a slight depression in LMP1 levels in 
sis1KO for the first two weeks. But there is no evidence of elevated LMP1 levels at any of the 
late time points. Expression of LMP1 in LCLs is higher in the LPKOw and sis1KO than for 
the WTw. 
3.11 Protein Expression Analysis in LCL grown from infected B cells 
 
LCLs obtained from the growth of infected primary B cells were seeded at 3x105 
cells/ml and harvested the next day. Proteins extracted from these cells were used for SDS 
PAGE. While in LPrevi LCLs, LP expression seems to be stabilized in smaller isoforms, the 
sis1KO mutants show LP with a similar size to WT HB9 (figure 3.18). For one of the LPrevi 
mutants along with HB9, it was not detected LP protein of any size, what can just be a result 













Figure 3.18: EBNA-LP expression in LCLs in a 12.5 % polyacrylamide gel. 
Although western blots in EBNA-3A -3B, LMP1 and EBNA-2 were also performed 
(not shown), the results were inconclusive. Instead of the full size EBNA-3A and EBNA-3B, 
I was able to detect two fragments of different sizes for each one of these proteins, with could 
be due to an apparent contamination of the primary Ab or the degradation of the proteins. 
Because LMP1 and EBNA-2 were detected from the same gels as respectively -3A and 3B, 
the presence of intense bands out of place didn’t allow for the detection of the second protein 
with the second reprobe. Due to lack of time and the usage of all the protein extracts, the 
westerns were not repeated. 
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Chapter 4: Discussion 
	
	 As mentioned before, the initial aim of the project was to generate three different 
mutants of sisRNA-1 and sisRNA-2 (see section 1.10) but only the sisRNA-1 KO was 
successful. The viral titres obtained from 293-SL producer cell lines were very low but after 
concentration they were enough to infect B cells. I showed that knocking-out sisRNA-1 
appears to reduce transformation efficiency, although no obvious effect at the viral gene 
expression levels were observed.  
4.1 Attempt to establish 6W repeat arrays failed for some of the mutants 
	
In the project, I was able to generate a recombinant EBV from which all of the 
sisRNA-1 introns were deleted, but was unable to complete the repeat arrays containing only 
the BsmB1 point mutation or only the triplet of BWRF1 polymorphisms. This failed at the 
assembly of the two 3W repeat sides to form a 6W repeat array, which is a simple step from a 
technical point of view that worked well for sisRNA-1 mutants but failed for unknown 
reasons for the other mutants. The assembly of the 6 repeat units systematically failed for two 
of the mutants, in the sense that despite the two fragments being able to assemble together, the 
number of repeats was spontaneously reduced.  
Cloning repetitive regions has its own specific challenges because of the instability of 
direct repeats. In order to reduce this problems, we cloned the repetitive regions in a specific 
vector and grew plasmids at a lower temperature (30 ºC). Looking at figure 3.2, one can 
speculate that the identical nature of the repeats somehow caused instability during the 
cloning process that allowed for two of the repeats to be ejected from the construct. This 
explanation does not necessarily account for the fact that the equivalent parental plasmid, also 
used to construct the C side (see figure 3.1) didn’t cause problems in that construct nor in the 
sis1KO mutants. The fact that different constructs of the Y side product of the first GA were 
not showing a proper BamHI restriction profile for the sisRNA-1point mutant and the 
sisRNA-2 triple mutant can be also related to the kinetic instability that causes some of the 
repeat units to be ejected when the two sides are assembled together (second GA).  
It is also possible that the quantity of DNA in the GA was not sufficient. The 
quantification of DNA was done using a nanodrop that does a basic UV absorbance analysis 
to determine the amount of DNA present. This DNA can be can be contaminated with single 
stranded DNA or RNA that gives a falsely high DNA concentration. When the DNA 
	 59	
quantification was repeated with a fluorimeter, the yields were in fact much lower than 
previously obtained (almost half). This happens because the absorbance-based assay 
quantifies all NTPs while the dyes used in the fluorimeter bind specifically to dsDNA. This 
leads to an obvious overestimation of the DNA concentration in a sample when using 
absorbance assays, if the DNA is degraded or contaminated with free nucleotides or RNA. If 
the condition of the DNA of the 3W Y side were bad, this could cause the ratios calculated for 
the 6W GA to be wrong and to affect the assembly process.  
4.2 Differences in the episomes rescued from the producer cell lines are not 
significant 
 
As mentioned, when episome rescue was performed for two of the clones obtained 
from the sis1KO mutants, there was a band at around 12 Kb that showed differences in size 
for some of the mini-preps when comparing to the parental BAC transfected into the 293-SL 
cells (see section 3.4). This band corresponds to a region in the BAC that contains the TR, the 
coding exons of LMP2 and the start of the BALF0 ORF. 
LMP2 was shown to be non essential to B cell infection or transformation in vitro 
(Kim & Yates 1993; Longnecker et al. 1992; Longnecker, Miller, Tomkinson, et al. 1993; 
Longnecker, Miller, Miao, et al. 1993), so it shouldn’t pose a problem if this region was 
somewhat shorter. 
BALF0 is an extended version of the BALF1 ORF: there are two in-frame methionine 
codons near the beginning of the BALF1 reading frame in EBV, the first of which was 
originally assumed to be the initiation site of translation at position 165,517 in the EBV 
genome. BALF0 is the name given to the ORF initiated at the first methionine. However, 
sequence analysis of BALF1 homologues from some closely related primate 
lymphocryptoviruses, indicates that only the second methionine codon is conserved. This 
observation, along with others reported by Bellows et al. (2002), seem to indicate that 
translation of BALF1 is initiated at the second methionine site. BALF1 is potentially 
important for cell survival as it was shown to be an antagonist of the Bcl-2 like  antiapoptotic 
proteins (Bellows et al. 2002). However, the region between BALF0 and BALF1 ORF 
doesn’t have any known roles related to invectivity, and since the repeat length variation is 
normal, the clones were still used to produce infectious particles. 
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4.3 Differences in viral titres might be a consequence of the lack of sisRNA-1 
	
As mentioned in section 3.6, the titres obtained from the 293 cell lines containing 
sis1KO mutants were consistently low. This could be either a biological consequence of the 
lack of the sisRNA-1 or a random effect caused by a bad producer cell line: the 293 cell 
clones can vary widely in their ability to produce virus. 
It is possible that the deletion of sisRNA-1 could be involved in one or more of the 
phenomena required for the virus DNA to replicate inside the cell, the packaging of the DNA 
in the capsid or the releasing of the viral particles from the host cell. The qPCR data showed a 
low viral titre for sis1KO, agreeing with the Raji infection data, which together seem to show 
that the number of DNA-containing particles is low, so the problem is not attributable to a 
decrease in infectivity of the particles but rather to an insufficient production of intact 
particles. This explanation is however very subject to speculation once producing viruses is a 
very unreliable and unpredictable protocol. Viral production can be affected by several factors 
related to the producer line conditions so it is impossible to know if the cell line was faulty or 
if the mutation causes the lytic production to decrease. 
Another possible explanation for the very low viral titres could be related to the loss of 
the ability of the virus to splice between W1 exons. A transcript splicing W1-W1-BHRF1 was 
described by the Flemington lab (O’Grady et al. 2016): during reactivation there is a splicing 
program across the W repeats, that produces transcripts containing no W2 exons, but instead 
splices between W1 exons of (possibly) adjacent repeats – W1-W1 splicing. They conjecture 
that this unique splicing programme confers an alternative 5’ UTR functionality rather than a 
protein-coding capacity, as no start codons were detected across the 2 ORF present in the W1 
exons. This novel splicing programme was detected by a combination of conventional 
Illumina short read next generation sequencing and Pac Bio long read data, allowing for the 
validation and annotation of polyadenylated transcript structure features across gene-rich 
genomes. The W1-W1 and W1-BHRF1 splice junctions were detected in both reactivated (ie 
lytic) Akata and Mutu cell lines, but not in latency III or uninduced latency I cells. These 
early transcripts have a peak 24 h after BCR crosslinking, in a 48 h time-course with early 
time points (0, 5 and 30 min, 1 h, 2 h, 4 h, 8 h, 24h and 48h). BHRF1 is a homologue of the 
anti-apoptotic Bcl-2 factor (Henderson et al. 1993), and is a potent inhibitor of apoptosis. If 
this protein is missing during the lytic cycle, it could cause the cells to die prematurely and 
not have enough time to produce and release viruses. This explanation is supported by Yee et 
al. 2011, as when they attempted to produce a BHRF1KO, the recombinant was not able to 
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produce viruses, although a virus knocked out for both BHRF1 and the nearby microRNAs 
was able to do so. Additionally, the BsmBI mutation alters the W2 splice acceptor (ccgtctcag 
to ccgactcag), which might disrupt the W1W-1 splicing in the lytic cycle. This could explain 
the low titres previously obtained in the LPKOi and LPrevi mutants by A. Szymula.  
4.4 Importance of infections in different donors 
	
The source of the B cells used for infections is detailed because there is thought to be a 
variation effect in the infection, that is donor dependent. As well as genetic variation, factors 
such as a donor’s age, previous infections, anti-viral treatments, EBV infection status among 
others can cause the infection to progress in a different way. For this reason, it is important to 
repeat the experiments in a representative number of donors in order to decrease the effect of 
donor variation. 
The fact that the observations of a phenotype of decreased transformation efficiency in 
early infection caused by sis1KO was seen in several infections from different donors 
reassures us that it is not an artefact caused by characteristics of one particular donor. 
4.5 Higher cell death by day 8 post-infection for LPKO and sis1KO 
The percentage of dead cells the sis1KO and LPKOw infections was much higher on 
day 8 than for the remaining viruses (figure 3.12). This may be due to a decrease in 
infectivity: if the viruses are somewhat less infectious, fewer cells are transformed to induce 
proliferation and more non-proliferating (uninfected) cells are left, so there are more cells to 
die, as resting B cells tend to die after a prolonged period in co-culture. If these mutations 
result in an increase challenge for the virus to enter the B cell or start expressing the viral 
proteins that allow transformation of the naive cells, the result would be a lower number of 
early infected cells or cells presenting the typical hyper proliferation profile. After around 3-5 
days in culture, B cells start to die, only the transformed ones survive. However, infectivity 
differences between the samples should be already controlled for by quantification by Raji 
infection. A second option is that there could be less expansion of the live cell pool for these 
mutants, when comparing with WT. Thus there are more cells growing that makes the live 
pool of cells larger relative to the size of the dead cell pool.  
A third possibility is that dividing cells are more likely to die without the action of EBNA-LP 
or sisRNA-1. This third option is the most interesting one biologically but would need some 
very careful quantitative experiments (mathematically model) to address to what extent the 
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first two options may be true. It would also be handy to look at the cell division numbers of 
the dead cells to see whether all the dead cells are essentially non-proliferated, in order to 
discard any other reason for higher dead cell numbers. This can be challenging as after cells 
die, they quickly start disintegrating, so the fluorescence that reflects their proliferation will 
become reduced. 
The fact that more cells died in the one-time Cell Trace experiment by day 8 for 
sis1KO when compared to the WT, is a clue that points to the sisRNA-1 playing a role in 
early infection stage. 
4.6 SisRNA-1 is not essential in transformation of B cells by EBV but it seems 
to improve early proliferation 
 
In terms of the B cell infection time course, sis1KO and LPKO seemed to be similar 
until day 7, then sisKO started to display bigger clumps but still lagged a bit behind the wild-
type infections in terms of cell density (figure 3.11). It is possible that the wild-types 
overgrew and started saturating the media by later time-points,  which could explain why the 
sis1KO catches up in terms of growth. It is importat to keep in mind that the direct 
observation of cell growth is subjective, and it tells us about differences in cell densities in 
given moments, but not about growth rates. For example, we don’t know exactly which cells 
in the clumps are dividing, but if we admit that only the surface of the clumps presents 
adequate conditions for the cells to proliferate at maximum rate, as bigger the clumps get, the 
smaller the percentage of the cells actually dividing in the sample, which means samples with 
smaller clumps will continue to display higher proliferation rates until the clumos reach a 
critical size. 
The differences between the sis1KO and WT in terms of how much they have 
proliferated by day 8 are clear (see figure 3.13), and consistent with what A. Szymula 
previously observed (dissertation 2016) that that LPrevi-infected cells had proliferated less by 
day 7 when compared to the WT. Because the LPrevi is a sisRNA-1 mutant it makes sense 
that it shares the characteristics of growth with sis1KO. Furthermore, she saw that the LPKOw 
mutants survived and were able to generate LCLs while none of the LPKOi did. All together, 
these two observations seem to show that there is a negative additive effect of the lack of LP 
protein and disruption of the sisRNA-1 and that the defect that was present in LPrevi was due 
to sisRNA-1 and not to sisRNA-2 or the SNPs. 
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4.7 B cells infected with LPrevi shown a delayed growth and ultimately died 
 
Against previous observations of the infection of B cells by LPrevi, I observed that 
LPrevi had a slower growth when compairing to all of the other infections and ultimatly 
started to show decreasing density and cell death (see figures 3.9 - 3.11). 
The volume of virus for each infection was calculated in order to obtain the same MOI 
for all the viruses. However, since calculations were based on the titres that were established 
at the time of the virus production and the LPrevi virus came from a batch of supernatant 
produced around 2 years prior the experiment and stored at 4 ºC, it is possible that the titres of 
the virus in the LPrevi supernatant used for the infection had dropped. 
 
4.8 Cp vs Wp usage 
 
My qPCR analysis did not identify any effect of LPKO or sis1 mutation on the relative use 
of Cp and Wp. There is a hint that Wp usage is slightly higher on day 4 in the sis1 mutants - 
LPrevi and sis1KO, but this observation would need many repeats to be confirmed (see figure 
3.15). No consistent differences were seen at other time points. In the established LCLs, there 
is a higher Cp activity which might be a real effect since the LCL experiments are better 
controlled. Because the cells are at different densities during the time-course, it is possible 
that the cell culture variations - caused by the different proliferation rates of the infected cells 
-  have compromised the data. In order to minimize this error, it would be essential to repeat 
the experiment several times. The LCLs presented in the graphics were the cell lines 
generated from the cells infected for this time-course. To minimize variation between the 
samples, the LCLs were seeded at a fixed density and harvested at the same time the next day, 
to allow the cells to recover from these manipulations. This method assumes that different 
LCLs recover from seeding and rates of entry into cell cycle are the same and that the cells 
don’t reach maximum density over this time. LCLs’ gene expression in this experiment is 
more reliable because it is more controlled in terms of errors and artefacts than the outgrowth 
data; it should not however be quantitatively compared to the remaining time-points. Some of 
Agnieszka’s findings showed that by day 2, Wp usage was higher and Cp was lower in the 
LPKO than the WT and that LPrevi, although they were not consistent. 
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4.9 LMP1 expression is not substantially different 
	
Some subtle differences were seen in LMP1 expression when compairing sisKO to 
WT: LMP1 expression starts later for the sis1KO and increases slower than WT. While WT 
shows the highest increase in LMP1 expression between day 4 and 8, in sis1KO the increase 
is only obvious between day 13 and 20.  
Early LCLs established from sis1KO (day 30 post infection) have a lower LMP1 
expression than WT, and similar to LPKO but later LCLs show a higher LMP1 expression for 
both the LP KO and sis1KO. However, due to the lack of replicates these observations do not 
have a strong significance. This data is not fully in agreement with data from A. Szymula first 
time-course (dissertation 2016) where she saw that by day 30, the LMP1 expression of 
LPKOw and LPrevi was much higher than WT and WTw; the levels of LPKO and LPrevi 
started by being much lower than WT on day 2 and continued increasing until they became 
higher than WT between day 16-30. By day 9 the LPKOw and LPKOi showed a much lower 
LMP1 expression than WT and WTw and LPrevi was in between the two groups. The later 
time-courses from A. Szymula (dissertation 2016) do not show the later increase in LMP1 
levels but consistently show the early difference. It is possible that the lack of replicates and 
SD between the replicates in my experiments are camouflaging any substantial differences in 
later time-points but the late LCL data agrees with the data from early Agnieszka’s LCLs and 
the lower expression of LMP1 from LPrevi and LPKO agrees as well. She observed that by 
day 9, the LPKOw and LPKOi showed a much lower LMP1 expression than WT and WTw , 
and LPrevi was inbetween the two groups. The effect can be due to a lack of LP in the 
LPKOs, once LP has been described to co-operate in EBNA-2 transactivation of the LMP 
promoters. It is curious that deletion of sisRNA1 has the same effect as knocking out LP, 
indicating that the sisRNA-1 might be involved in the co-activation as well. This hypothesis 
seems to be re-ensured by the fact that LPrevi, that carries a mutation in sisRNA-1 is slightly 
impaired in LPM1 expression by day 8.  
Although there is no clear effect on LMP1, if we were to make sense of these findings, 
they could explain the proliferation impairment by day 8, by which time LMP1 does induce 
both pro- and antiapoptotic genes whose balance seems to permit survival during LMP1’s 
induction and maintenance of proliferation (Dirmeier et al. 2005).  
 However new evidence seems to point that LMP1 expression and its characteristic 
NFκB activity levels are relatively low until approximately two weeks post infection (Price et 
al., 2012). This same study, hints that LMP1 promoter activity may be low due to the lack of 
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activity or expression of host factors implicated in the activation of the LMP1 promoter. 
Much more interesting for this work than understanding the reasons causing the delay in 
LMP1 expression, is to ask how proliferating B cells early after infection survive without 
NFκB anti-apoptotic signaling. A very interesting theory on this is suggested by Altmann & 
Hammerschmidt (2005) that BHRF1 and BALF1 proteins, produced in the LMP1-low phase, 
are responsible for supporting immediate B cell survival and rescue from apoptosis in very 
early infection. 
This study also shown that while BALF1 and BHRF1 are functionally redundant, 
having at least one is essential to LCL establishment. Transcripts from the two genes are 
detectable at 24h post-infection and they continue to be detected by RT-qPCR until 3 weeks 
post-infection, although in a northen blot gel, the levels seem to decrease significantly 
between day 7 and 10 post-infection. Cells infected by viruses with both genes knocked out 
died within 8 days, while single KO mutants (of BALF1- or BHRF1-) are capable of yielding 
LCLs but require slightly higher viral titres than WT viruses. 
 If this is the case, and sis1KO disrupts the BHRF1 splicing as hypothesised earlier 
(section 4.3), that could explain why in early infection the percentage of dead cells is much 
higher for sis1KO than for WT and also why proliferation is slightly impaired but doesn’t 
prevent the establishment of LCLs. Many more replicates would be required in order to verify 
if the small differences are reproducible. 
4.10 Protein expression is not conclusive 
	
Western blotting of LPrevi and WTw LCLs is not at all in agreement with previous 
observations by Dr. White, where he saw an LP ladder with isoforms of different sizes.  
It is possible that other isoforms are present in these LCLs but in very low concentrations 
when compairing to the protein concentration in full lysates. Sometimes it is possible to see 
one single band with some LCLs when they have been in culture for a long time, because the 
cell lines can adapt to use preferential transcripts. Also given that the MOI used was low, it 
might be that the LCLs were more clonal, while the ones expressing several isoforms could be 
more polyclonal. It is not understood yet if the production of different isoforms of LP is made 
by the same cells or if different cells make different isoforms. 
 Because of the variation in this data when compared with the predicted results, the 
other observations became very unreliable. However, it is noteworthy the consistency showed 
by the 4 LCLs obtained from infections with sis1KO, that all display the same size of LP.  
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Chapter 5: General Conclusions 
 
As mentioned in the materials and methods, working with repeat regions is very 
technically challenging because of the complex strategies required to introduce the mutation 
in every repeat and because of the natural instability of these regions when manipulated. 
Furthermore, the modification of viral BACs and their purification is time-consuming and 
subject to all kinds of unpredicted difficulties. Furthermore, making viruses from EBV BACs 
is unreliable as it is require to generate a cell that supports latency and is simultaneously able 
to be induced into lytic cycle, as there are no known permissive cells for EBV. 
The fact that the viral titre for the sis1KO was never more than 10 GRU/µl whereas 
the one of the LPKOs gave over 1000 GRU/µl, and most other viruses were over 100 
GRU/µl,  made it impossible to perform experiments without a previous expansion of the 
producer cell lines, and large scale virus production followed by the viral concentration. 
The process of making producer cell lines is fickle and to some point difficult to 
control, but we now know that there is a W1W1 splice that might be disrupted by the deletion 
of sisRNA1, so the low titre could be due to lack of BHRF1, that would otherwise protect the 
cell from premature cell death. The disruption of BHRF1 expression could be a hypothesis 
that explains all of the observations made during the course of this work, although an 
unknown function of the novel RNA could also be a suitable cause for the phenotype.  
All together the delayed outgrowth of infected cells, the reduced number of cell 
proliferations in cell trace assay and the higher dead cell numbers point to sis1KO playing a 
role in early infection, although is not essential for the transformation process. However 
further experiments would be required to understand at what stages the sisRNA-1 is acting. It 
could be during the activation and growth of the B cell, or the immune evasion after infection 
or even the entry in a hyperproliferative state. The percentage of cell death was also higher in 
sis1KO than for the WT viruses, which could support any of the mentioned hypothesis. 
The experiments performed show that the sisRNA-1 KO viruses are defective during 
early infection but they were insufficient to draw conclusions about the effect on viral genes.  
They might be useful as preliminary findings to drive future experiments on the role of 
the alternative splicing and the function of intron-derived non-coding RNAs in the 




Chapter 6: Future Work 
	
 6.1 Finish the construction of mutant viruses and repeat infections 
	
For a formal confirmation of the link between the lack of sisRNA-1 and the observed 
phenotype it would be essential to produce the BsmBI mutants as well as a BHRF1 mutant to 
exclude an effect related to an altered sisRNA-2. A revertant of the sis1KO would also be 
required since only by excluding the effect of secondary site mutations we can map the 
phenotype back to a lack of sisRNA-1.  
To complement the work done so far, it will be important to repeat the B cell 
infections and the time course experiments a few times, in order to determine if the initial 
observations are consistent. Biological replicates are required specially for the qPCR, in order 
to minimize the experiment related errors. The infections have to be repeated several time in 
multiple different donors to obtain statistically relevant data on the proliferation assays, cell 
death and transcriptomic analysis. To minimize variation in proliferation caused by the lack of 
control on cell densities, it would be useful to optimize the protocol on cell growth during the 
time-course to have equal cell densities at each time point. This is technically difficult since 
any type of intervention at this early times after infection could alter the normal behaviour of 
the infection. If the cell densities are the same to start with and the infection efficiencies are 
also equal, any differences in cell density can be directly attributed to the ability of the virus 
to induce proliferation. However the strategies to neutralize this differences and keep the 
same conditions for all of the samples in later time-points (such as adding different volumes 
of media, seeding cells at different densities, etc) would themselves lead to variability in the 
experimental conditions. 
6.2 Following up on the defective features of sisRNA-1 
 
6.2.1 Making producer cell lines 
New virus preps from a new batch of producer cell lines would be useful to obtain 
more viral particles and to see if the titres are reproducibly low. For this it would a better 
control to ultracentrifuge all virus preps at the same time and conditions (for example the use 
of bacitracin, same rotation speed on ultracentrifugation). To test if the low viral titres in 293 
cell lines were a consequence of disrupting the BHRF1 protein production, it would be useful 
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to add a BHRF1 expression cassette to the producer cell lines when they are induced into the 
lytic cycle, to see if their ability to make virus is improved.  
In the future, we would want to mutate the sisRNA-1 by disrupting its short stem-loop, 
in a way that wouldn’t interfere with the splicing, to analyse if the structure of the sisRNA is 
relevant for its function and also produce other point mutants with different types of 
mutations in sis1 which we would expect to (by extension of the revi virus) share the 
properties of the sis1KO in some degree.  
6.2.2 Testing transformation efficiency 
To check if the lack of the W1W1 splice early after infection is relevant, the approach 
would be testing the transcripts on day 1 and 2 after B cell infection to see if the W1W1 splice 
is present (and W1W1BHRF1). Then, to confirm whether the missing splice option is why the 
sis1KO is defective in transformation, we could test BHRF1 transcripts early after infection 
by qPCR and see whether sis1KO is lower than WT; then for further confirmation, a double 
KO of both sisRNA-1 and BHRF1 would be produce to check if knocking out both genetic 
element generates similarly defective viruses and the combination makes no additional 
difference.  
By complementing the transformation of sis1KO with a BHRF1 lentivirus, and 
checking if proliferation improves, we would be able to attribute the transformation defect 
down to W1W1 splicing to BHRF1, or to a function of sisRNA-1. Another option could be to 
compare the BHRF1KO produced by Hammerschmidt and see if the effect is similar to the 
sis1KO. 
Complementing a sis1KO transformation with a sisRNA-1-expressing construct or 
lentivector could also be interesting, but may be difficult to make in a way that guarentees the 
correct processing of the intronic RNA. 
6.3 Long term analysis of sisRNA-1 and sisRNA-2 
 
It would be relevant to solve the cloning problems that impeded the production of the 
sisRNA-2 mutant and perhaps try to integrate the data obtained by Samantha Correia (phD 
student in Paul Farrel’s lab) fort a sisRNA-2 mutant virus with a KO hairpin to understand 
what is the role of the predicted sisRNA-2. She has so far seen that the virus lacking the large 
hairpin from the W repeats is severely defective, not being able to transform B cells and 
produces consistently very low titres. To verify if sisRNA-2 is in fact present in LCLs (which 
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as so far not been proven) it would be required to develop an efficient northen blot 
experiment. This could be informed by analysis of RNAseq data to look for junctions to see if 
sis2 is further processed like HSV LAT seems to be, or PacBio sequencing for long reads, 
although this might not work due to the hairpin, which is resistant to conventional Sanger 
sequencing (Richard di Palermo, personal communication) to detect it in the cells. The 
combination of data on the role of both sisRNA-1 and sisRNA-2 of EBV, could contribute to 
a more solid knowledge about the potential role of this genetic elements in viral genomes. 
6.4 Conclusion on the future work and time-frames 
To summarize, a lot of work is still required to formally prove that sisRNA-1 has an 
effect in enhancing EBV’s ability to promote B cell transformation. 
In the short-term (6 months), it is important to exclude any other possibilities 
regarding the cause of the observed phenotype in my experiments. For that, building the 
sisRNA-1 revertant and BWRF1-triple and a BsmBI mutants, that were one of the aims of 
these project that were not accomplished, is the first goal. In the medium-term (up to 1 year), 
the goal would be repeat the infections, time-course, proliferation experiments and qPCR 
analysis with the new mutants and the old ones to obtain more consistent data. 
Generating other mutants, such as viruses in with the structure of sisRNA-1 is disrupted 
would allow to understand if the structure plays any role in the sisRNA function. The 
generation of these mutants could be done in parallel with others. 
Due to recently published evidence found that the phenotype observed could be caused 
by disruption of the W1-W1-BHRF1 splicing instead of the lack of sisRNA-1, the second step 
would be to generate new producer cell lines of sisRNA-1KO viruses both in the presence and 
absence of a BHRF1 expressing cassette and test the virus ability to transform cells. This 
could be a work for another 4 months. 
Transformation with viruses in presence and absence of both sisRNA-1 and BHRF1 
(perhaps delivered using lentiviruses) and different KO viruses could be another way of 
checking if the effect is due to lack of splicing would be another medium-term goal. 
As long-term goals, analysing the role of sisRNA-2 as well as the difference in 
transcriptomics from the sisRNA-1 mutants would be time-consuming but could lead to 




























Table I: Reagents and solutions composition organized by protocol 
      Protocol     Reagent/ Solution 
 
Composition 
Gel electrophoresis 20 x TBE (1 l) 242.3 g Tris-HCl, 14.9 g Na2EDTA.2H2O, 61 g boric 
acid, up to 1l with ddH2O 
 
Bacterial growth Super Broth – SB (1 l) Bactotryptone 12 g, Yeast Extract 24 g, glycerol 4 ml, 
ddH20 up to 950 ml (autoclaved), 50 ml 20 x KPB 
20 x Potassium Phosphate 
Buffer -KPB (1l) 
46 g KH2PO4, 243 g K2HPO4 
Make up to 1 l with ddH2O and autoclave. 
Luria Broth (LB) Agar 0.5% NaCl, 1% Tryptone, 1% Yeast extract, 1.5% agar, 
ddH2O (autoclaved before adding antibiotics) 
Antibiotics 
(Stock solutions) 
Ampicillin - Amp  100 mg/ml in 70% EtOH (1000x) 
Cloramphenicol - Cm 12.5 mg/ml  in 70% EtOH (500x) 
Kanamycin - Kan 50 mg/ml in ddH2O (1000x) 
Cyclosporine A - Cyc  
Bacitracin- Bac 10 mg/ ml in PBS  (x100) 
Hygromicyn B - Hyg 50 mg/ml in PBS               
Tetracyclin - Tet 5 mg/ml in 70 % EtOH (500x) 
CsCl Maxi-Prep GTE 50 mM glucose, 50 mM Tris HCl pH8, 50 mM EDTA 
(autoclaved) 
P2 (Alkaline SDS) 0.2 M NaOH; 1% SDS (prepared fresh) 
P3 300 ml 5 M potassium acetate, 57.5 ml acetic acid, up 
to 500 ml of ddH20 
T10E25  25 mM EDTA, 10 mM Tris HCl pH 8 
(autoclaved) 
TE-saturated butanol 1:2 TE to butanol, mixed and leave to separate. TE 
added until butanol was saturated 
CsCl Mix 36.9 g CsCl in 50 ml of T10E25 
Mini-Prep STET 8 % sucrose, 5 % triton X-100, 50 mM EDTA, 50 mM 
Tris HCl pH8 
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B-cell Purification MACS Running Buffer PBS pH 7.2, 2mM EDTA, 0.5 % BSA 
MACS Rinsing Buffer PBS pH7.2, 5 mM EDTA 
Wash Buffer 1 bottle of RPMI supplemented with 1% FCS 
1% BSA/ PBS 1 % BSA in 1 x PBS 
Protein Extraction RIPA 5x 750 mM NaCl, 5 % NP40, 2.5 % DOC, 0.5 % SDS, 
0.25 M tris-HCl pH=8.0 (autoclaved) 
Lysis Buffer 1x RIPA containing 100 µM PMSF, protease inhibitor 
cocktail (1 tablet in 2 ml of ddH20; use 1ml/25ml of 






Resolving Gel 7.5 %  
(4 gels) 
7.5 ml Acrylamide/Bis-acrylamide 40%,  
7.5 ml Tris-HCl pH=6.6, 
15 ml ddH20, 15 µl APS, 15 µl 10 % SDS, 300 µl 
TEMED  
Resolving Gel 12.5 %  
(2 gels) 
6.25 ml Acrylamide/Bis-acrylamide 40%, 3.75 ml Tris-
HCl pH=6.6, 5 ml ddH20, 7.5 µl 10% APS, 7.5 µl 10% 
SDS, 150 µl TEMED 
Stacking Gel 6% 
 (4 gels = 20 ml) 
3 ml  Acrylamide/Bis-acrylamide 40 %, 5 ml  Tris-HCl 
pH=6.8, 11.6 ml  ddH20, 200 ul 10 % SDS, 200 µl 10 % 
APS, 20 µl TEMED 
Sample Buffer 2.9 ml ddH2O, 0.5 ml 1M Tris-HCl pH 6.8, 0.5 ml 10 % 
SDS, 1 ml 100 % glycerol, 50 µl 2-mercaptoethanol, 
bromophenol blue (until desired color intensity) 
 
Running Buffer 10x 30.3 g Tris base, 144 g glycine, 10 g SDS, filled up to 1 
l with dH2O 
 
Transfer Buffer (1 l ) 100 ml of 10 x running buffer, 234 ml EtOH, up to 1 l 
with ddH20 
PBS tween (PBSt) 0.1 % TWEEN20 in 1x PBS 







Table II.I: Antibodies used in the western blots 
Antigen Antibody Species Source Working Concentration 
EBNA-3A - Sheep abcam 1:1000 
LMP1 CS1-4 Mouse abcam 1:2000 
EBNA-3B 6C9 Rat Supernatant of hybridoma cell lines 1:10 
EBNA-2 PE2 Mouse Supernatant of hybridoma cell lines 1:50 
EBNA-LP JF186 mouse Supernatant of  hybridoma cell lines 1:500 
EBNA-3C A10 Mouse Supernatant of hybridoma cell lines 1:10 
mouse IgG - Sheep DAKO 1:2000 
Rat IgG - Rabbit DAKO 1:2000 
Sheep IgG - Rabbit DAKO 1:2000 
	
Table IIII: Primer and probe sequences used in qPCR  
Target Primer ID Primer sequence Probe 
Wp W0 fw CGCCAGGAGTCCACACAAAT  
Sybr (No probe) 
 
Wp/Cp W1/W2 rv GAGGGGACCCTCTGGCC 
Cp C1C2 fw AATCATCTAAACCGACTGAAGAAACAG  
Qp AI39QXR Costume design assay 









GCTTAGCCAGTAACCCAGCACT  YH  
CCCAACCACAGGT
TCAGCAAAACTTT 
 YH-rev TGCTTAGAAGGTTGTTGGCATG 
RPLP0 RPLP0 fw ACTCTGCATTCTCGCTTCCT Sybr (No probe) 
 RPLP0 rv GGACTCGTTTGTACCCGTTG 
ALAS1 ALAS1 fw GGATTCGAAACAGCCGAGTG Sybr (No probe) 
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